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ABSTRACT OF DISSERTATION

A NOVEL ROLE FOR THE TUMOR-SUPPRESSOR PAR-4 IN REGULATION
OF ADIPOGENESIS AND OBESITY
Prostate Apoptosis Response-4 (Par-4) is a conserved and ubiquitous
tumor-suppressor factor which can selectively induce apoptosis in tumor
cells, while leaving normal cells unaffected. While Par-4 is well established
as a tumor-suppressor, there have yet been no formal investigations as to
whether it has a physiologic role in normal tissues.
Early observations of Par-4 knockout mouse lines yielded that the adult mice
displayed significant weight gain and fat accumulation compared to their wildtype counterparts while on a conventional chow diet. Interestingly, obese mouse
and human subjects were found to exhibit reduced expression of Par-4 in
adipose tissue as well as lower levels of secreted Par-4 in their plasma,
compared to samples collected from lean human subjects.
Subsequent in vitro experiments would show that loss of Par-4 has significant
impact upon adipogenesis. Mechanistically, Par-4 loss during adipogenesis in
cell culture correlated inversely with expression of the adipogenic transcription
factor PPARγ.
Subsequent experiments would demonstrate that Par-4
transcriptionally represses PPARγ at the promoter level.
Thereby, we conclude that Par-4 regulates adipogenesis and lipid accumulation
through transcriptional repression of the PPARγ promoter. This research utilizes
novel models and may be used as the basis for Par-4-mediated therapies for
obesity and metabolic disease.
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CHAPTER ONE: INTRODUCTION
It has been nearly a century since Otto Warburg and colleagues published their
observations regarding dysregulated metabolic activity in carcinoma cells. They
found that tumor cells utilize inordinate amounts of glucose and ferment this
glucose to lactate regardless of oxygen availability. This ‘aerobic glycolysis’ was
the first major connection between altered metabolic states and cancer (Liu et al.,
2010).

Whilst most subsequent studies focused upon glucose/lactate

conversion, attention would later be directed to the role played by fatty acid
metabolism and obesity.

Several types of tumor cells display accelerated

lipogenesis (Furuta, Okuda, Kobayashi, & Watabe, 2010) and fatty acid oxidation
(Carracedo, Cantley, & Pandolfi, 2013).
Besides the changes in fatty- acid metabolism, obesity is linked with several
types of cancer, including liver, esophageal, colon, post-menopausal breast
carcinoma and possibly that of the prostate (Kelesidis, Kelesidis, & Mantzoros,
2006).

Some hypothesized mechanisms include increased acid reflux

contributing to esophageal cancer (Q. Chen, Zhuang, & Liu, 2012) or chronic
inflammation promoting liver cancer (Sun & Karin, 2012).

However, other

possible mechanisms may involve changes to insulin signaling or the tumor
microenvironment through interactions with adipose tissue.

One significant

conceptual shift in adipose biology is the modern understanding that adipose
tissue should not merely be considered a passive reservoir for energy storage,
but rather can be described as an endocrine organ in its own right (Huerta,
2006). Adipose tissue secretes important regulatory hormones like leptin and
1

adiponectin (Q. Chen et al., 2012), as well as inflammatory mediators like TNFα
or IL-6 (Sewter, Digby, Blows, Prins, & O’Rahilly, 1999). Further: adipose tissue
can act upon proximal tumors in a paracrine manner to influence growth or
invasive potential (Wolfson, Eades, & Zhou, 2015) (Dirat et al., 2011).
Furthermore,

phenotypic

changes

observed

amongst

tumor-associated

adipocytes indicate crosstalk between breast tumors and proximal adipocytes. In
vitro experiments demonstrate that breast cancer cells co-cultured with
adipocytes can stimulate de-lipidization of the adjacent adipocytes, and utilize the
newly-freed free-fatty-acids to support proliferation and invasion of the tumor
cells (Balaban et al., 2017; Laurent et al., 2017).
With all this in mind, it should not be surprising that cellular metabolism can be
affected by altered expression of oncogenes or tumor-suppressor genes- such as
Ras, Myc, (Liu et al., 2010) (Faubert et al., 2013) or p53 (Liang, Liu, & Feng,
2013).

This can also be extended to obesity or generation of fat cells

(adipogenesis). As one pertinent example: p53 can suppress transcription of
genes required for lipogenic enzymes (Yahagi et al., 2003), can inhibit adipocyte
differentiation (Molchadsky et al., 2013) and inhibits high-fat diet- induced weight
gain in mice (Wang, Zhao, Gao, Mei, & Wu, 2013).
As our group focuses upon the tumor-suppressor Prostate Apoptosis Response4 (Par-4), we undertook a series of studies to determine whether Par-4 might
possess a physiologic regulatory role distinct from its known tumor-suppressor
functionality. Long-term observations of whole-body-Par-4 knockout mouse lines
yielded that the adult mice displayed significant weight gain and fat accumulation
2

(as well as numerous physiologic hallmarks of obesity), compared to their wildtype counterparts while on a conventional chow diet. This obese phenotype was
recapitulated in an adipocyte-specific Par-4 knockout mouse model. Subsequent
in vitro experiments would show that loss of Par-4 has a significant impact upon
adipogenesis.

Mechanistically, we found through Western blotting that Par-4

loss correlated inversely with protein expression of the adipogenic transcription
factor PPARγ in both in vitro and in vivo models.
combination

of

qPCR,

luciferase

reporter

Refining our model, a

assays

and

chromatin

immunoprecipitation experiments would demonstrate that Par-4 transcriptionally
represses PPARγ at the promoter level. Conversely, we also found that obese
human subjects were found to exhibit reduced expression of Par-4 in adipose
tissue as well as lower levels of secreted Par-4 in their plasma, compared to
samples collected from lean human subjects. Similar results were observed in
dietary obese mice. Based on our experimental data, I hypothesize that Par-4
regulates adipogenesis and lipid accumulation through transcriptional repression
of the PPARγ promoter. These findings are significant as they describe a tumor
suppressor which acts as a novel regulatory factor for adipogenesis and obesity,
as well as a novel regulatory factor for PPARγ. Furthermore, these experiments
demonstrate reduced expression and secretion of a tumor suppressor (Par-4) by
obesity.

This suggests that loss of Par-4 is a possible contributing factor in

tumorigenesis or tumor progression in obese subjects.

I further posit that a

future benefit of this research would be the development of Par-4-mediated
therapies for obesity and metabolic diseases.

3

Prostate Apoptosis Response-4 (Par-4)
The Par-4 (PAWR) gene (Figure 1.1) encodes a ubiquitously expressed tumor
suppressor protein which can induce apoptosis via an array of intrinsic or
extrinsic pathways. A particular point of therapeutic interest is the novel finding
that Par-4 can be secreted by normal cells under conditions of endoplasmic
reticulum (ER) stress, inhibition of autophagy as well as p53 activation and
inhibition of NF-κB. This secreted Par-4 can then selectively induce apoptosis in
tumor cells in a paracrine or possibly autocrine manner, while leaving normal or
immortalized cells unaffected (Burikhanov et al., 2009). The discovery of Par-4
was borne out of an effort to identify therapeutically exploitable tumor suppressor
genes.

The laboratory of Vivek Rangnekar at the University of Kentucky

performed differential hybridization experiments on cDNA from the AT-3
androgen-independent prostate cancer cell line after treatment with the Ca2+
ionophore ionomycin.

This experiment resulted in the induction of an early

apoptotic response gene (designated Par-4). Further experiments yielded that
Par-4 gene expression is upregulated in rat prostatic cells in response to
androgen deprivation and that Par-4 is not upregulated by growth stimulation,
growth arrest or necrosis.

These results demonstrated that Par-4 is an

apoptosis-associated gene or tumor suppressor (Sells et al., 1994).

Clinical

evidence of Par-4’s status as a tumor suppressor can be gleaned from the
findings that Par-4 has been shown to be downregulated or mutated in renal cell
carcinoma, neuroblastoma, endometrial and breast cancer (Cook et al.,
1999)(Shrestha-Bhattarai & Rangnekar, 2010).
4

Additional studies have

demonstrated that reduced Par-4 expression and activity correlates with
unfavorable chemotherapeutic treatment prognosis and reduced radiosensitivity
of breast and colon tumors (Alvarez et al., 2013; Contract, Mackley, & Irby, 2011;
Pereira et al., 2013).
Par-4 structure
Par-4 is not only ubiquitously expressed across tissues but is found in a wide
range of vertebrates, ranging from humans, mice and pigs to fish, birds and frogs
(Nadia El-Guendy & Rangnekar, 2003).

Par-4 is ordinarily translated in the

cytosol in normal cells, but under conditions of ER stress or in tumor cells, Par-4
can be translated by ribosomes in the ER. Par-4 has also been observed to
display a high degree of homology within the nucleic acid and peptide sequences
between species. For simplicity’s sake, we shall focus here on the human, rat
and mouse Par-4 peptide sequences, which are approximately 40kDa and 340
amino acids (AA) long in humans, 332 AA in rats and 333 AA in mice. Similarly,
Par-4 possesses a number of 100% sequence conserved functional domains
(Figure 1.2). These domains include (in order from amino terminal to carboxyterminal): two putative nuclear localization sequences (NLS1 and NLS2) the
"Selective for Apoptosis of Cancer Cells" (SAC) domain, a C-terminal leucine
zipper (LZ) domain and a C-terminal nuclear export sequence (ShresthaBhattarai & Rangnekar, 2010). Additionally, the localization and activity of Par-4
can be affected by the phosphorylation status of certain conserved residues by
the kinases ζPKC, PKA (at Thr 155 in rats, Thr 163 in humans) and AKT (Ser
249 in rats, Ser 228 in humans) (Shrestha-Bhattarai & Rangnekar, 2010). NLS1
5

is only six AA in length, and oddly, deletion of this domain does not prevent Par4’s nuclear entry, downstream activity (eg: preventing NF-κB transcriptional
activity) or apoptosis, rendering NLS1’s function to be unknown at this time.
NLS2, by contrast is 17 AA long, and had been found to be essential for
translocation of Par-4 from the cytoplasm to the nucleus. It has been shown that
deletion of NLS2 will prevent nuclear entry, changes to NF-κB transcriptional
activity and apoptosis (Nadia El-Guendy, Zhao, Gurumurthy, Burikhanov, &
Rangnekar, 2003).
The SAC domain was identified through a series of structure-function
experiments performed by El-Guendy et al. to establish the functions of Par-4’s
domains.

Deletion analysis of rat Par-4 yielded a 59 AA core domain

encompassing amino acids 137-195, which was found to represent the minimal
functional domain which would selectively induce apoptosis in cancer cells. This
study as well as later ones would find that Par-4 mediated apoptosis is
predicated upon its NLS2-mediated nuclear entry as well as phosphorylation of
the T155 residue (rat Par-4) by cAMP (Gurumurthy, Goswami, Vasudevan, &
Rangnekar, 2005). As it happens: the SAC domain contains both NLS2 and
T155 (T155 in rats, T156 in mice, and T163 in humans), thus rendering the SAC
domain as a prerequisite for Par-4-mediated apoptosis. As will be mentioned
shortly, the SAC domain also contains the binding region for the chaperone
protein GRP-78, and is thus vital for extracellular-Par-4-mediated apoptotic
activity. As further evidence of SAC’s relevance to cancer: Zhao et al. generated
mice which overexpress a GFP-tagged SAC domain. The resulting animals were
6

normal in all major respects, but the animals exhibited a high degree of
resistance to spontaneous or induced tumorigenesis or experimental metastasis
(Zhao et al., 2007, 2011). This series of experiments suggest a potential
therapeutic role for Par-4 or SAC in the future.
The 41 AA, C-terminal leucine zipper domain is not essential for apoptosis.
However, it is responsible for a number of Par-4-protein interactions which
conspire to sensitize a cell for apoptosis (Nadia El-Guendy et al., 2003). The LZ
domain of Par-4 interacts with zinc finger domains of such proteins as Wilms’
tumor protein (WT-1) (Johnstone et al., 1996) ζPKC (Nadia El-Guendy et al.,
2003), p62 and topoisomerase 1 (TOPO-1)(Goswami et al., 2008). Some of
these interactions indicate that Par-4’s LZ can sensitize cells to apoptotic
pathways and also negatively regulate pro-survival pathways through interactions
with such factors as TOPO-1, WT-1 and / or ζPKC. The LZ may also contain a
nuclear exclusion sequence, causing Par-4 to be generally localized to the
cytoplasm.
Par-4 -mediated apoptosis
Intracellular Par-4- mediated apoptotic activity requires nuclear translocation and
inhibition of NF-κB (N. El-Guendy, Zhao, Gurumurthy, Burikhanov, & Rangnekar,
2003). This downregulation of NF-κB is founded on the observations that Par-4
can bind the atypical protein kinase ζPKC (Díaz-Meco et al., 1996). This ζPKC is
otherwise capable of phosphorylating and tagging the inhibitory IκB peptide for
proteosomal degradation. It has been further shown that NF-κB transcriptional
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activity is inhibited by Par-4 phosphorylation by ζPKC (Moscat, Rennert, & DiazMeco, 2006).
Experiments on the apoptosis of prostate cancer cells by El-Guendy, et.al
demonstrated that apoptosis is preceded by migration of Par-4 from the
cytoplasmic compartment to the nucleus.

Later immunoprecipitation

experiments would show that the AKT1 kinase associates with Par-4 (Goswami
et al., 2005). When AKT phosphorylates rat Par4 at S249 (S228 human), this
promotes binding to the chaperone protein 14-3-3, causing cytoplasmic
sequestration of Par-4 (Brunet et al., 1999) and subsequently preventing
apoptosis (Sledziona & Rangnekar, 2017) (Figure 1.3 A).
Interestingly, Par-4 can also act through extrinsic apoptotic pathways.

For

example: Par-4 stimulates translocation of surface death receptors Fas/CD95
and Fas ligand (FasL) to the cell surface (Chakraborty, Qiu, Vasudevan, &
Rangnekar, 2001). The Fas-mediated apoptotic pathway can then proceed via a
caspase-8 dependent manner (Beere, 2005).
One particularly novel feature of Par-4 is the discovery that Par-4 can be
secreted into the extracellular environment under conditions of endoplasmic
reticulum (ER) stress (Burikhanov et al., 2009), p53 activation (Burikhanov et al.,
2014) or inhibition of NF-κB (Burikhanov et al., 2013). Further: this secreted Par4 is capable of subsequent, cancer cell-selective induction of apoptosis in a
paracrine or autocrine manner.

This discovery has profound implications for

enhancing current standard-of-care cancer therapies.
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A series of salient experiments by Burikhanov et al. demonstrated that not only
could Par-4 be secreted after treatment with tunicamycin (an ER stressing
agent), but eventually that transferring conditioned media (CM) from tunicamycin
treated cells to untreated cell populations will selectively induce apoptosis in PC3 cancer cells, while leaving normal or immortalized BPH-1 cells unaffected
(Burikhanov et al., 2009). This property of the CM was found to be abrogated
through preapplication of Brefeldin A (an inhibitor of the classical ER-to-golgi
body secretory pathway) to the treated cells. The apoptotic effect of the CM was
neutralized through pre-incubation with Anti-Par-4 antibodies- verifying that this
apoptotic activity was Par-4 dependent.
Mechanistically, this behavior was found to be dependent upon the chaperone
protein GRP-78 (AKA: BiP or Glucose-Related Peptide-78), which is ordinarily
localized to the ER. This factor was confirmed as a binding partner of Par-4
though pulldown experiments, as binding to GST-tagged Par-4 from PC-3 lysates
(Burikhanov et al., 2009). Additional studies by this research group found it was
essential that GRP-78 be present at the cell surface for apoptosis by extracellular
Par-4, which indicated co-localization of the two peptides. Specifically-it was
found that GRP-78 binds Par-4 at a the SAC domain. The Authors posit that
when Par-4 is bound to surface GRP-78, that GRP-78 recruits the FADD adaptor
protein, which in-turn activates the Caspase-8 to Caspase-3 cascade as this
process was found to be activated by extracellular Par-4 (Sledziona &
Rangnekar, 2017) (Figure 1.4). Basal cell surface expression of GRP-78 has
been previously reported to be specific to tumor cells (Arap et al., 2004; Raiter,
9

Yerushalmi, & Hardy, 2014) as a result of endogenous ER stress and is
consequently thought to be a major mechanism behind the tumor-specific
apoptotic response of Par-4. Building upon this, it was previously mentioned that
extracellular secretion of Par-4 can be induced by NF-κB inhibition or p53
stabilization. Yeast-two hybrid and co-IP studies by Burikhanov et al. indicated
that Par-4 can bind another chaperone protein- UACA (Uveal Autoantigen with
Coiled-Coil Domains and Ankyrin repeats). Transcription of UACA is upregulated
by NF-κB and downregulated by active p53 (Burikhanov et al., 2013, 2014).
UACA, in turn binds to and sequesters Par-4 and GRP-78 in the cytoplasm,
thereby modulating Par-4 mediated apoptotic activity (Burikhanov et al., 2013;
Sledziona & Rangnekar, 2017) (Figure 1.3 B).
Obesity: a ‘systemic’ problem
Obesity (abnormal or excessive fat accumulation) is a complex condition, which
involves multiple organs and tissues normally involved in maintenance of energy
homeostasis. Chief amongst these are the adipose tissue (storage), liver (lipid
biosynthesis, gluconeogenesis), pancreas (glucose homeostasis) and brain
(feeding and physical activity). Obesity can involve disrupted feedback between
these tissues, particularly in chronic cases, ultimately manifesting as metabolic
syndrome.
The adipose tissue is of course responsible for the storage of triacylglycerides
(TAG), and release of free fatty acids (FFA) into circulation. However, adipose
tissue expansion also triggers regulatory feedback mechanisms.

10

Adipocytes

express and secrete the hormones leptin and adiponectin. Leptin acts upon the
hypothalamus to suppress food intake by stimulating feelings of satiety in the
individual (Klok, Jakobsdottir, & Drent, 2007).

Circulating leptin is commonly

increased during obesity, but it appears that the hypothalamus becomes resistant
to leptin’s effects although the mechanism is under debate (Enriori, Evans,
Sinnayah, & Cowley, 2006). Adiponectin, however has more widespread targets.
The adiponectin receptors (AdipoR1 and AdipoR2) increase glucose uptake of
target tissues by increasing surface translocation of the glucose transporter
GLUT4, but also act via the AMPK pathway to increase fatty-acid oxidation
(Yamauchi et al., 2002).

Adiponectin also possesses anti-inflammatory

capabilities, as it can inhibit NF-κB activation, thereby reducing expression of
TNFα, IL6, and increasing IL-10. Adiponectin expression is reduced in chronic
obesity (Arita et al., 1999; Asayama et al., 2003), possibly through promoter
hypermethylation (A. Y. Kim et al., 2015).
The liver has a vital role in energy homeostasis through storing carbohydrates as
glycogen, synthesizing glucose via gluconeogenesis and by acting as the primary
site of lipid biosynthesis (de novo lipogenesis- or DNL).

The liver is also

responsible for packaging FFA into TAG, which are released into circulation and
taken up by peripheral tissues like muscle and adipose for energy and storage.
Altered

expression

levels

of

lipogenic

enzymes

can

lead

to

obesity

experimentally (Strable & Ntambi, 2010). Also, DNL has been demonstrated to
be a contributor to fatty liver disease (Sanders & Griffin, 2016).
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The pancreas regulates glucose homeostasis through secretion of insulin from βcells and glucagon from α-cells. Insulin is secreted in response to feeding or
elevated plasma glucose and binds its receptor (IR) on most tissues to promote
translocation of glucose transporters to the plasma membrane (Fu, Gilbert, & Liu,
2013). This translocation promotes glucose influx. Furthermore, insulin strongly
promotes lipogenesis and DNL is also increased under conditions of insulin
resistance (Sanders & Griffin, 2016).

Glucagon-secreted in response to low

blood glucose signals the liver to convert stored glycogen to glucose for release
(Ramnanan, Edgerton, Kraft, & Cherrington, 2011) (figure 1.5).
Adipogenesis
Adipogenesis is the process by which mesenchymal stem cells will differentiate
into fat storage cells (adipocytes).

These progenitor cells are generally first

influenced by extracellular signals, which eventually trigger a cascade of
transcriptional regulatory factors, which then initiate the production of
downstream effectors.
Adipogenesis may be divided into two primary stages: commitment and terminal
differentiation (Cristancho & Lazar, 2011). The process of commitment is not
perfectly understood, but appears be regulated by canonical and non-canonical
Wnt signaling and such possible external influences as the stiffness of the
extracellular matrix. Regarding Wnt signaling, generally speaking, the canonical
Wnt signaling axis of receptor LRP6 and ligand WNT10B suppress adipogenesis
by inhibiting PPARγ induction (Kawai et al., 2007; Takada, Kouzmenko, & Kato,
2009), whereas the non-canonical ligand Wnt5B can promote differentiation
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through suppressing B-catenin translocation, which is requisite for canonical
signaling (Kanazawa et al., 2005). The perivascular fibroblasts in the Adipose
compartment capable of adipogenesis are characterized by CD24+, CD29+,
CD34+ and SCA1+ (Cristancho & Mitchell, 2011). In response to adipogenic
stimuli, these committed white preadipocytes undergo a epigenomic transition.
This transition is characterized by induction of the adipogenic master regulator:
the nuclear receptor Peroxisome Proliferator-Activated Receptor Gamma
(PPARγ) (Cristancho & Lazar, 2011) (Figure 1.6).
The process of terminal adipogenesis is marked by growth arrest, morphologic
changes, and induction of several members of the CCAAT/ enhancer binding
protein family of transcription factors (C/EBP)- starting with C/EBPβ and C/EBPδ
(Rosen & Spiegelman, 2000). In vitro, this is rapidly followed by PPARγ and
C/EBPα, and followed, in turn by the appearance or upregulation of fatty acid
synthase (FASN), acetyl CoA carboxylase (ACC), malic enzyme, insulin receptor,
GLUT4 and fatty acid binding protein adipocyte protein 2 (aP2 / FABP4) (Rosen,
Walkey, Puigserver, & Spiegelman, 2000).

What essentially develops is a

transcriptional cascade in which PPARγ and C/EBPα reinforce the expression of
one another, as the PPARγ promoter contains a C/EBPα binding site, enhancing
its activity (Lee & Ge, 2014a).

Contrariwise, PPARγ activation increases

transcription of the C/EBPα gene (Zuo, Qiang, & Farmer, 2006). Additionally,
C/EBPα and PPARγ are often found to be simultaneously bound to the common
promoters of downstream genes upregulated during adipogenesis- this
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simultaneous binding may allow synergistic promoter activity. (Madsen,
Siersbaek, Boergesen, Nielsen, & Mandrup, 2014).
Experimentally, in vitro adipogeneis experiments are performed utilizing
committed pre-adipocyte fibroblast lines, such as the 3T3-L1 cell line. However,
It’s also possible to use primary mouse embryonic fibroblasts (MEFs) (RuizOjeda, Rupérez, Gomez-Llorente, Gil, & Aguilera, 2016). Both of these models
were utilized for the adipogenesis experiments detailed in this thesis.

The

process of terminal differentiation can be accomplished through first growing the
cells to confluence in order to induce cell growth arrest, followed by addition of a
combination of insulin supplementation, the elevation of cyclic AMP (cAMP) via
the

phosphodiesterase

inhibitor

Isobutyl

methyl

xanthine

(IBMX),

the

thiazolidinedione (TZD) PPARγ agonist troglitazone, and the glucocorticoid
dexamethasone (Dex). The rate of differentiation can be tracked visually and
lipid accumulation can be visualized through cell fixation, followed by Oil-red-O
staining of neutral lipids.
Stimulation of adipogenesis
During stimulation of the adipogenic pathway, insulin appears to act through
cross-reactivity with the IGF-1 receptor- leading to phosphorylation and
stimulation of Ras and AKT(Xu & Liao, 2004). AKT can, in turn, phosphorylate
the FoxO1 transcription factor, inhibiting its activity. FoxO1 has been previously
found to inhibit adipogenesis, possibly through promoter inhibition of cell cycle
inhibitors and other adipogenic genes (Nakae et al., 2003).
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Both IGF-1 and

insulin signaling also remain significant for maintenance of mature adipose
tissue. Adipose tissue-specific knockout of either receptor in mice have been
found to result in dystrophy of white adipose tissue, coupled with severe diabetes
and fatty liver. (Boucher et al., 2016).
Activation of cyclic AMP (cAMP) is also known for its ability to induce and
enhance adipogenesis (E D. Rosen & Spiegelman, 2000).

Petersen, et. al

describe interactions with multiple central pathways to stimulate transcriptional
and cytoskeletal changes. The Authors detail that as cAMP activates PKA, PKA
will inhibit Rho kinase activity (which normally suppresses adipogenesis through
attenuation of the Insulin/ IGF-1pathway). Further, cAMP appears to bind to a
specific guanine exchange protein (Epac), which can induce changes to
cytoskeletal

organization,

adhesion

molecules

and

extracellular

matrix

interactions through inhibition of Rho kinase characteristic of adipocytes
(Petersen et al., 2008). Finally, cAMP stimulates the transcription factor CREB
(cAMP-response element binding protein), which can promote the transcription of
the C/EBP’s and PPARγ.

As a side note: although IBMX experimentally

upregulates cAMP, the actual in vivo stimulus for cAMP elevation is uncertain at
this point (Petersen et al., 2008; J.-W. Zhang, Klemm, Vinson, & Lane, 2004)
(Figure 1.7).
Paradoxically, MAPK can also suppress adipogenesis through inhibitory
phosphorylation of PPARγ and its heterodimerization companion RXR (Rosen &
Spiegelman, 2000).
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The glucocorticoid receptor (GR) does not appear to be an absolute requirement
for adipogeneis, although administration of Dex can certainly accelerate the
process in vitro. A recently published manuscript by Park and Ge indicate that
Dex upregulates multiple pro-adipogenic genes in early adipogenesis, including:
C/EBPα, C/EBPβ, C/EBPδ, and PPARγ. The Authors go on to demonstrate
through ChIP-Seq that Dex-activated GR directly binds at or near those gene
loci. In addition, GR recruits the acetyltransferase p300 (CBP) to C/EBPβ-bound
enhancer regions- further upregulating transcription of the C/EBPβ target genes
(Park & Ge, 2017).
Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
The adipogenic master regulator PPARγ is a nuclear hormone receptor and
transcription factor which is encoded by a gene located on chromosome 6 in
mice (Chromosome 3 in humans) (“NCBI-Gene-PPARG,” 2017). This gene is
responsible for modulating transcription of several genes related to insulin
response, lipid transport and metabolism and adipogenesis (i.e.: GLUT4, the
insulin receptor (IR), FABP-4 and Fatty Acid Synthase-FASN); further: mutations
in PPARγ

promote lipodystrophy and hyperinsulinema

(Hegele, 2005).

Structurally, the PPAR family members contain four vital domains (listed Nterminus to C-terminus): a transactivation domain called Activation Function 1
(AF1), a DNA-Binding Domain (DBD), a hinge region and ligand binding domain
(LBD) (Figure 1.8) (Azhar, 2010). Upon synthesis, PPARγ will be shuttled to the
nucleus (Umemoto & Fujiki, 2012) and heterodimerize with another nuclear
hormone receptor- the Retinoid X Receptor (RXR) (Rosen et al., 2000). This
16

assembly binds a DNA promoter response element (PPAR Response ElementPPRE) and modulates transcriptional activity. This assembly can recruit either
transcriptional

coactivator

or

corepressor

factors,

and

thereby

up-or

downregulate transcripion of the target gene. However, generally speaking when
not ligand bound, this assembly will generally act as an repressive complex, but
will also behave as a

transactivation complex when ligand bound (Choi &

Bothwell, 2012) (Figure 1.9). While TZD compounds are quite effective synthetic
agonists, the actual endogenous ligands of PPARγ are not presently well
characterized. Previously hypothesized candidate ligands generally represent a
series of dietary, free fatty acid derivatives or prostaglandins. These factors,
however were later found to exhibit poor binding affinity, low local availability or
have eluded detection in vivo (Tzameli et al., 2004). The most effective in vivo
ligand candidates to date appear to be nitrated lipid compounds such as
unsaturated fatty acids and arachidonic acid derivatives- which have been
modified by reactive nitrogenous species.

These molecules may incidentally

represent a new class of signaling molecules relevant to inflammation and
cardiovascular disease (Villacorta, Schopfer, Zhang, Freeman, & Chen, 2009).
However more research will be necessary to determine whether these represent
the PPARγ ligands responsible for modulating adipogenesis in vivo.
PPARγ has been found to occur primarily as two isoforms- designated PPARγ1
and PPARγ2 (Zhu et al., 1995). These isoforms differ in a few respects. For
example: PPARγ1 is encoded by eight exons, whereas PPARγ2 is coded by
seven. Although the amino acid sequences encoded by the six C-terminal exons
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in both isoforms are identical, the PPARγ2 peptide possesses a 30 amino acid
sequence N-terminal to the ATG site for PPARγ1. As such, both isoforms begin
transcription at different promoter sites (Zhu et al., 1995).

Not only do the

promoter sites differ, but the two isoforms exhibit disparate tissue distribution:
PPARγ1 is rather widely distributed at a low level of expression but is
concentrated in insulin-responsive tissues such as skeletal muscle, heart and
liver. PPARγ2, by contrast is restricted mostly to adipose tissue (Mukherjee,
Jow, Croston, & Paterniti, 1997), with some expression observed in liver and
skeletal muscle (Vidal-Puig et al., 1996). As the PPARγ1 promoter has been
observed to contain additional CpG islands, it has been speculated that changes
in promoter hypermethylation may be responsible for this tissue-specific
distribution (Zhu et al., 1995). There is also significant chromatin remodeling
observed in the PPARγ2 promoter in the first few hours of adipogenic stimulation;
particularly around the promoter regions occupied by C/EBPα,β and PPARγ (Lee
& Ge, 2014a). This chromatin remodeling has been found to be dependent on
cAMP and PKA activity, and addition of IBMX is sufficient for loosening the
chromatin of the PPARγ2 promoter (Lee & Ge, 2014b).
PPARγ promotes transcription of many genes related to metabolism, lipogenesis
and adipogenesis, such as GLUT-4 (Marín-Juez, Diaz, Morata, & Planas, 2013),
VLDLR (Tao, Aakula, Abumrad, & Hajri, 2010) adiponectin (Iwaki et al., 2003),
and possibly FASN (as evidenced by promoter binding sites for PPARγ1 and 2
(“Search ChIP-qPCR Assay FASN,” n.d.)). Also PPARγ2 is capable of enhancing
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transcription of SREBP1, which is in turn known to transcriptionally upregulate
FASN (Schadinger, Bucher, Schreiber, & Farmer, 2005).
While adipose tissue expansion can be manifested through increasing the total
number of adipocytes (hyperplasia) through adipogenesis, expansion can also
come about through increasing the size of the individual adipocytes
(hypertrophy). This in turn could come about through one or more of the following
processes: de novo lipogenesis, increased lipid uptake and/or reduced lipolysis.
De novo lipogenesis
Besides dietary fats, another source of fatty acids in the body is de novo
lipogenesis the biological synthesis of fatty acid chains from acetyl-CoA.
Physiologically, this is generally the domain of the liver and dysregulation of this
process is implicated in fatty liver disease (Sanders & Griffin, 2016).

As it

happens: adipocytes not only store lipids which have been exported by the liver,
but also are themselves capable of DNL from the catabolism of glucose, pyruvate
and glutamine (Collins et al., 2011). In fact there is some evidence that DNL is
necessary for the maturation of developing adipocytes (Collins et al., 2011). This
regulation may be rather complicated, however, as adipose expression of
lipogenic enzymes appears to be inversely related to obesity (Collins et al.,
2011), but hepatic DNL can be accelerated in hyperinsulemic subjects (Sanders
& Griffin, 2016). This may be explained by the finding that insulin stimulates
lipogenesis through increased transcription of SREBP1 and FAS through the
PI3K/ AKT/ mTORC signaling axis (Rui, 2014).
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PPARγ2

is

also

capable

of

inducing

lipogenesis

in

adipocytes

and

experimentally, in liver (Schadinger et al., 2005; Y.-L. Zhang et al., 2006) through
enhanced expression of SREBP-1, FASN and acetyl Co-A carboxylase member
(ACC1). Contrariwise, the products of these DNL pathways can act as ligands
for PPARγ activation. A basic pathway is detailed below.
Sterol-regulatory element binding proteins (SREBPs) are transcription factors
which bind to sterol-response promoter elements in the nucleus and activate
transcription of multiple lipogenic genes (Y.-M. Kim et al., 2010). Cytosolic ACC1
catalyzes the addition of a bicarbonate- derived carboxyl group to acetyl Co-A in
order to convert this substrate to malonyl CoA as the rate-limiting step for FA
biosynthesis (Davis, Solbiati, & Cronan, 2000).

The resulting malonyl Co-A

becomes the substrate for cytosolic FASN, which will then add acetyl Co-A to
malonyl Co-A (utilizing NADPH) to ultimately synthesize 16C palmitate (J. Chen
et al., 2016). ELOVL6 (Fatty acid elongase 6)- will convert palmitate to 18C
sterate (Matsuzaka & Shimano, 2009). Palmitate and sterate are both saturated
FA’s, however, SCD1 (Stearoyl Co-A desaturase 1) utilizes NADH to catalyze
formation of monounsaturated fatty acids (delta-9 cis) from palmitoyl Co-A and
stearoyl Co-A (Paton & Ntambi, 2009). The newly- synthesized FA’s can be
coupled to a glycerol backbone derived from glycerol-3-phosphate (G3P) in an
acylation reaction catalyzed by GPAT (Acyl-CoA:G-3-P acyltransferase),
generating lysophosphatidic acid (Takeuchi & Reue, 2009).

Subsequent

acylation reactions to generate diacylglycerol and triglycerol are catalyzed by
acylglycerolphosphate acyltransferase (AGPAT)- followed by dephosphorylation
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of phosphatidic acid by Lipin-1 (Reue & Dwyer, 2009) and diacylglycerol
acyltransferase (DGAT), respectively (Yen et al., 2008) (Figure 1.10).
Lipolysis and β-oxidation
Obviously, as white adipocytes function as storage vessels for TAG, excess
adipose TAG accumulation leads to obesity and associated metabolic disorders.
As a requisite for the mobilization of the stored lipids, the stored TAG’s are
hydrolyzed sequentially back into free fatty acids and glycerol (Ahmadian, Wang,
& Sul, 2010; Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E., & Sul,
2007). Lipolysis is accomplished by a series of lipases and hydrolases, such as
hormone-sensitive lipase (HSL), which responds positively to β-adrenergic
agonists or ACTH and also responds negatively to insulin (Kraemer & Shen,
2002).

Additional catabolic enzymes include adipose triglyceride lipase

(Desnutrin) and triacylglycerol hydrolases. Finally, fatty acid transport out of the
cell is accomplished through binding with the chaperone protein adipose fatty
acid binding protein (FABP/aP2). (Duncan, R. E., Ahmadian, M., Jaworski, K.,
Sarkadi-Nagy, E., & Sul, 2007).
Ironically, obesity is associated with increased basal lipolysis, although βaderengic stimulated lipolysis is decreased (Duncan, R. E., Ahmadian, M.,
Jaworski, K., Sarkadi-Nagy, E., & Sul, 2007). Insulin receptor activation inhibits
adipocyte lipolysis. Consequently, loss of insulin sensitivity (for example, as a
consequence of obesity) will fail to impede lipolysis. It is further believed that
TNFα, which is often increased in obese adipose tissue can decrease perilipin
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expression (see next paragraph) and thereby allow accelerated basal lipolysis
(Ahmadian et al., 2010; Cawthorn & Sethi, 2008).
The main lipid droplet in adipocytes is protected from lipase activity by being
covered with the perilipin family of proteins. When perilipin is phosphorylated by
PKA as a consequence of β-Adrenergic receptor activation, it alters its
confirmation to allow exposure of the droplets to lipases.

Insulin, however

counters this activity by PI3K/ AKT stimulation, which dephosphorylates cAMP
and thereby inhibits the PKA-mediated phosphorylation of perilipin and HSL
(Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E., & Sul, 2007).
FFAs are released from the adipocytes and transported through the bloodstream
whilst bound to serum albumin proteins. Glycerol is exported via aquaporins like
AQP7 into circulation. This glycerol can be transported back to the liver to be
utilized for gluconeogenesis or re-esterified to fatty-acyl CoA to fuel TG
biosynthesis (Rui, 2014). After circulating FFAs reach their target cells, they
enter the cells with the aid of lipid transporters like FATP1 (SLC27A1) or CD36
(Martin et al., 2000; Wu et al., 2006). the FFA's then undergo β-oxidation in order
to be catabolized into Acetyl-CoA subunits to be fed into the TCA cycle and
subsequent oxidative phosphorylation (or be shunted from the TCA cycle into
other biosynthetic pathways).

The enzyme carnitine palmitoyltransferase 1

(CPT1), located on the outer mitochondrial membrane binds long-chain fatty
acid-CoA to carnitine, whereupon this molecule is translocated into the
mitochondrial matrix whereupon, CPT2 cleaves off acyl-CoA and carnitine (Wakil
& Abu-Elheiga, 2009). There is an additional form of regulation at the level of
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CPT1; another related carboxylase enzyme (Acetyl-coenzyme A carboxylase 2ACC2), converts acetyl-CoA to malonyl-CoA at the mitochondrial membrane,
which inhibits CPT1 and prevents β-oxidation (Wakil & Abu-Elheiga, 2009)
(Figure 1.11).
Obesity, inflammation and insulin resistance
In obese subjects, one observes increased adipose turnover and release of lipids
which are immunogenic in nature (Iyengar, Gucalp, Dannenberg, & Hudis, 2016).
As adipose tissue expands beyond the ability of the circulatory system to support
it, the adipocytes are prone to hypoxic stress.

Furthermore, increased FFA

levels in adipocytes are linked to ER stress, leading to cell death. This cell stress
and death promotes macrophage infiltration into the adipose tissue and triggers
release of immunogenic factors such as TNFα and IL-6 by the adipocytes as well
as the macrophages (Cawthorn & Sethi, 2008; Iyengar et al., 2016).

The

released FFAs are also be taken up by infiltrating macrophages- causing them to
become foam cells. FFAs also activate the toll-like receptor family member TLR4
on the macrophage surface, triggering expression of TNFα and IL-1β, further
exacerbating the inflammatory response (Iyengar et al., 2016). Adipocytes have
also been found to release Monocyte Chemoattractant Protein (MCP-1)
coincident with increasing adipodosity. MCP-1 can then recruit monocytes like
macrophages, as well as neutrophils and lymphocytes (Deshmane, Kremlev,
Amini, & Sawaya, 2009).

This immunogenic environment promotes loss of

insulin sensitivity, perhaps leading to type-2 diabetes (Shoelson, Lee, & Goldfine,
2006). Although the mechanism is unclear, TNFα reduces transcription of the
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insulin receptor substrate protein IRS1 and GLUT4 and thereby reduces insulin
sensitivity of the tissues (Stephens, Lee, & Pilch, 1997). This reduced insulin
sensitivity thereby necessitates insulin hypersecretion by the β-cells. Over the
long term however, chronic inflammation can lead to β-cell dysfunction and
failure (Prentki & Nolan, 2006).
Excessive adipodosity also affects the liver. Excessive triglyceride storage in
hepatocytes observed during non-alcoholic fatty liver disease in humans is
sourced from a combination of the adipose tissue (60%), DNL (26%) and diet
(15%) Lipids released from the adipose tissue can circulate back to the liver and
accumulate there.

The circulating inflammatory cytokines produced during

obesity also act systemically and might affect the liver, reducing insulin
sensitivity.

Even in an insulin resistant state, insulin will continue to trigger

hepatic DNL (Haas, Francque, & Staels, 2016) (Figure 1.12).
It has also been well established that obesity increases the likelihood of
developing cancer, in addition to less favorable treatment prognoses. Cancer
associated adipocytes display an activated phenotype, characterized by
increased expression of TNFα, IL-1, IL-6 and matrix metalloproteases (MMPs)which promote invasion (Dirat et al., 2011). The tumor may also benefit from the
readily available fatty acids for catabolism and anabolism (Hoy, Balaban, &
Saunders, 2017; Wen et al., 2017).
Given otherwise equivalent caloric intake and physical activity, normal weight
/adiposity is dependent upon a balance between adipogenesis, lipogenesis and
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lipolysis. This research tract will describe our observations of the effects of the
Par-4 tumor suppressor upon these pathways, which together describe a novel
regulatory role for Par-4.
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Figure 1.1: Introns/exons of human and mouse Par-4.
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Figure 1.2: Functional domains of human, rat and mouse Par-4
The functional domains of Par-4 are highly conserved. This diagram shows the
two Nuclear Localization Sequences (NLS1, and NLS2), the SAC domain, and
Leucine Zipper (LZ).
Figure source: (Hebbar, Wang, & Rangnekar, 2012). Used with permission.
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Figure 1.3: Regulation of Par-4 by the PI3K/AKT pathway.
Phosphorylation of Par-4 by AKT promotes binding with 14-3-3, and promoties
cytoplasmic sequestration (A).
Par-4 secretion can be promoted by p53 upregulation or NF-κB inhibition,
through inhibition of NF-κB-mediated transcription of UACA. UACA ordinarily
binds Par-4 and prevents it from secretion (B).
Figure source: (Sledziona & Rangnekar, 2017). Used with permission.
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Figure 1.4: Extrinsic apoptosis pathway as mediated by Par-4.
Par-4 and GRP-78 can be associated

in the ER (A), however they can be

localized to the plasma membrane via the classic secretory pathway (B). Par-4
can then be released into the surrounding media. This circulating Par-4 can bind
to surface GRP-78 (C), and initiate a FAS-like apoptotic caspase cascade (D).
Figure source: (Sledziona & Rangnekar, 2017). Used with permission.
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Figure 1.5: Signaling and fatty acid transport between the Adipose tissue,
pancreas, muscle, and brain
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Figure 1.6: Wnt signaling in pre-adipocyte commitment.
Canonical Wnt signaling (Wnt10b/LRP6) axis (A) enhances β-Catenin signaling,
which in turn downregulates C/EBPα /PPARγ transcriptional activity. By contrast,
the non-canonical Wnt signaling pathway enhances pre-adipocyte commitment
by inhibiting β-Catenin signaling (B), and in-turn permitting C/EBPα /PPARγ
transcriptional activity to proceed (C).
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Figure 1.7: Stimulation of adipogenesis
Stimulation of adipogenesis involves multiple signaling pathways. Vitally, under
these conditions, the insulin/IGF-1 axis can stimulate cell-cycle inhibition (A).
cAMP signaling acts through multiple axes to stimulate transcription of target
genes (B).

The transcription factors C/EBPα and PPARγ can promote

transcription of each other and also produce the genes necessary for adipocyte
maturation (C). This process can be inhibited by external signals for cell growth
which block PPARγ transcriptional activity by upregulating the MAPK pathway
(D).
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Figure 1.8: PPARγ protein domains
Human PPARγ domain structure, showing the AF1 transactivation domain, DNA
binding domain (DBD), hinge domain and ligand binding domain (LBD). PPARγ2
is 30AA longer than PPARγ1 as it differs at the first exon due to alternative
splicing.
Amino acid positions from (Azhar, 2010).
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Figure 1.9: PPARγ Activity
PPARγ can act as both a transcriptional co-repressor and co-activator. PPARγ
heterodimerizes with RXR at PPAR response elements at the promoter for target
genes and can complex with corepressor (A) or coactivator elements (B)
depending on whether a ligand is bound to the complex.
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Figure 1.10: Pathways of de novo lipogenesis.
Acetyl CoA can be generated as the end product of glycolysis or the derived from
the TCA cycle (A). It can be used as a raw material for cholesterol biosynthesis
(B), as well as generating fatty acids (C).

These fatty acids can be joined

sequentially with G3P to form phosphatidic acid, DAG and TAG (D).
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Figure 1.11: Lipolysis, FFA circulation and β-oxidation
The central lipid droplet of adipocytes is protected by Perilipin proteins, which
can be activated through phosphorylation and allow access to lipases (A). The
cleaved FA are transported out of the cell and enter the circulation (bound to
albumin proteins) (B). The target cells uptake FA through transport proteins like
CD36, transported to the mitochondria and metabolized (C). Also, note how
cytosolic ACC1 generates malonyl-CoA for FAs to be utilized for β-oxidation,
whereas ACC2 on the mitochondrial membrane generates malonyl-CoA to block
β-oxidation (D).

36

Figure 1.12: Obesity, inflammation and insulin resistance crosstalk
Adipose tissue in obese subjects (A) releases immunogenic factors which
stimulate macrophages (B). This can affect the function of the liver (C), the
peripheral tissues (D) and the pancreas (E).
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Project Objectives:
Par-4 has been previously well established and examined as a tumor
suppressor.

In this dissertation, I set out to investigate potential physiologic

functions for Par-4 in normal animals. Preliminary observations indicated that
Par-4 knockout mice are significantly overweight compared to wild-type controls.
This dissertation will describe my phenotypic observations and the findings of
functional studies that investigate the hypothesis that Par-4 regulates key genes
involved in lipid accumulation and/or adipogenesis.

These observations are

significant as they describe a novel regulatory role for Par-4, with implications for
future research into obesity-associated tumor promotion and its suppression by
Par-4.

The following specific aims were pursued:
1. To determine the physiologic function(s) of Par-4 in normal mice
2. To determine the clinical relevance of the phenotype associated with Par4 loss
3. To identify the mechanism by which Par-4 loss causes the observed
phenotype through cell culture and mouse models
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CHAPTER TWO: THE PAR-4 TUMOR SUPPRESSOR INHIBITS
ADIPOGENESIS AND OBESITY VIA TRANSCRIPTIONAL REPRESSION OF
PPARγ
INTRODUCTION
Par-4 is a highly conserved, ubiquitously expressed tumor suppressor protein,
found in multiple cellular compartments- including the cytosol, endoplasmic
reticulum and nucleus (Burikhanov et al., 2009; Chaudhry, Singh, Parent, &
Asselin, 2012; Nadia El-Guendy et al., 2003). Par-4 can be secreted by normal
or tumor cells and this secreted Par-4 is capable of selectively inducing apoptotic
activity on tumor cells via a paracrine or autocrine pathway (Burikhanov et al.,
2009). Par-4 is capable of interacting with such diverse proteins as WT-1,
GRP78 and ζPKC.

Furthermore, Par-4 has been previously shown to affect

transcription of certain genes, such as inhibition of Bcl-2 through binding the
Wilm’s tumor protein WT-1 (Cheema et al., 2003).
Although previous studies have firmly established Par-4 as a tumor suppressor
protein, there is little data available at this point which assign broader
physiological functions to Par-4. Given the ubiquity of Par-4, combined with its
capability for multiple protein-protein interactions and transcriptional regulatory
capability, we hypothesized that Par-4 possesses a broader physiologic role. To
this end, we undertook a long-term study comparing growth rates of Par-4 wildtype and Par-4 knockout mice. The purpose of this dissertation is to detail our
process and our findings.
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We compared morphologic and phenotypic characteristics for Par-4 constitutive
whole-body knockout mice to age-matched wild-type control animals and found
the knockout animals to be of significantly greater mass compared to controls.
Further investigation found the knockout mice to be carrying far greater fat mass,
with several other markers for chronic obesity and insulin insensitivity likewise
observed. A series of in vitro experiments demonstrated that Par-4 can inhibit
the differentiation of primary and immortalized mouse fibroblasts into adipocytes
and that conversely, expression of Par-4 would be inhibited during adipogenesis.
In vivo studies utilizing tissues harvested from obese humans and dietary obese
mice indicate downregulation of Par-4 expression and secretion in obese
subjects. These findings provide interesting implications for generation of obesity
as well as obesity-associated cancer.
Mechanistically, we have been able to narrow down the myriad of potential
pathways involved by comparing next-gen RNAseq data from the liver tissue
obtained from Par-4 wild-type and Par-4 knockout mice. Western blotting for
candidate factors prompted us to focus upon elevated expression of the
transcription factor Peroxisome-Proliferator-Activated Receptor γ (PPARγ) under
conditions of Par-4 depletion. PPARγ is a master regulator of adipogenesis and
is critical for this pathway.

A series of quantitative, real-time PCR (qPCR),

luciferase reporter assays and chromatin immunoprecipitation experiments
prompted me to ascribe these effects upon adipogenesis to transcriptional
repression of the PPARγ2 promoter by Par-4.
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MATERIALS AND METHODS
Animal experiments
Whole- body Par-4 knockout mice were generated as follows: C57BL/6
background floxed Par-4 mice (designated Par-4fl/fl) were developed by Taconic
Biosciences. These mice contain loxP sites flanking the second exon of Par-4.
These animals would be crossed with a ROSA-26 Cre recombinase mouse.
After genotyping the resulting offspring, the heterozygous offspring (designated
Par-4+/-) would be crossed, so that a number of the resulting offspring will have
exon 2 of Par-4 excised in both alleles (designated Par-4-/-) (Figure 2.1 A). All
offspring were genotyped before use (Figure 2.1 B). Western blotting of the
spleen, liver, lung, kidney and MEFs have been used to verify that tissue
expression of Par-4 is knocked-out (Figure 2.1 C).
Adipocyte-specific conditional Par-4 knockout mice were generated as follows:
Par-4fl/fl mice were crossed with mice containing a Cre recombinase gene
controlled by an adiponectin promoter (designated Ad-Cre), obtained from
Jackson Labs (Figure 2.2).

After genotyping the offspring, heterozygous

offspring would be crossed, so that a number of the resulting offspring will have
exon 2 of Par-4 excised (designated Par-4/AKO) in the adipocytes.
Energy expenditure and body composition
Two-month old experimental mice were housed in individual metabolic cages. A
TSE Labmaster indirect calorimetry system (TSE-systems Inc.; Chesterfield, MO)
was used to simultaneously quantify energy expenditure, energy intake and
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locomotor activity.

Whole-body composition parameters (total body fat, lean

body mass, body fluids and total body water, were measured using an EchoMRI100 Body Composition Analyzer unit (EchoMRI; Houston, TX). The metabolic
cages and EchoMRI equipment were located at the University of Kentucky
Center of Research in Obesity and Cardiovascular Disease, supported by an
Institutional Development Award (IDeA) from the National Institute of General
Medical Sciences of the National Institutes of Health under grant number
P20GM103527.
Oral Glucose Tolerance Tests (OGTT) and plasma insulin measurements
After six hours of fasting, experimental mice would have blood collected and
tested via tail-vein bleeding immediately prior to administration of 2g/kg glucose
as a 25% glucose solution via oral gavage (Time= 0 minutes). Blood glucose
was measured using a TRUEresult glucometer (Trividia Health; Ft. Lauderdale,
FL). Additional blood glucose measurements were obtained at 15, 30, 60 and
120 minutes post-glucose administration.
At each timepoint, blood aliquots would be obtained with heparinized capillary
tubes and stored in 1.5 ml tubes containing 5 µl of 10% sodium citrate solution on
ice, which are centrifuged to extract the plasma fraction. Plasma insulin levels
for each timepoint were measured using a mouse ultrasensitive ELISA kit (Alpco;
Salem, NH) according to manufacturer's instructions. ELISA plate readings of
OD450 nm were obtained using a Spectramax M2 plate reader, running Softmax
Pro 5.4.3 and standardized to a 5-parameter logistic curve.
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All animals were housed in the University of Kentucky Animal facility and all
experiments were conducted under an Institutional Animal Care and Use
Committee-approved protocol in accordance with the NIH Guide for the Care and
Use of Laboratory Animals.
Analysis of plasma lipid levels
Measurements of plasma triglycerides (TG) and total cholesterol were conducted
through use of enzymatic colorimetric assays. TG levels were determined by
measuring degradation of plasma glycerol by glycerol kinase and glycerol-3phosphate oxidase after hydrolysis of TG to glycerol and fatty acids (GPOHMMPS).

Cholesterol levels were determined by measuring degradation of

cholesterol by cholesterol ester hydrolylase. Both kits were supplied by Wako
Diagnostics; Mountain View, CA, and assays were performed according to
manufacturer’s instructions. Analysis for both lipid tests was based upon OD600
nm, subtracting OD700 nm (reference wavelength values), and fit to a 5-point
standard curve.
Cell culture
Primary Mouse Embryonic Fibroblasts (MEFs) were obtained from Par-4+/+ and
Par-4-/-mouse embryos at embryonic day 13 and maintained in Dulbecco's
Modification of Eagle's Medium (DMEM) (Mediatech, Inc.; Manassas, VA)
supplemented with 10% Fetal Bovine Serum (DMEM+10% FBS), (Sigma Aldrich;
St. Louis, MO).

43

Short-hairpin RNA mediated knockdown of Par-4 was performed as follows: Par4 sh-RNA and control sh-RNA were inserted into a pLKO.1 vector, which was in
turn packaged into lentiviral particles for delivery.

The sh-RNA genes were

transduced into A549 and Hop92 human lung cancer cells from ATCC, cultured
in RPMI (Mediatech, Inc.; Manassas, VA) +10%FBS, and selected under 3μg/ml
puromycin (Sigma Aldrich).
Adenovirus-mediated Par-4 expression experiments were performed as follows:
GFP-Par-4 and control GFP DNA sequences were inserted into a pCMV-Ad5
vector, which was in turn packaged into adenoviral particles for amplification and
delivery. Par-4-GFP fusion and GFP control genes were transduced into 3T3-L1
cells, cultured in DMEM +10%FBS.
Adipocyte differentiation
Differentiation of adipocytes from MEFs was adapted from a protocol provided by
Fei, et.al (2011)(Fei, Bera, Liu, Xiang, & Pastan, 2011). Briefly: MEFs would be
grown in 6-well plates under DMEM+10% FBS. Once the cells are two days
post-confluence, the media would be replaced with adipocyte differentiation
media (vis: DMEM+10% FBS further supplemented with 10µg/ml bovine insulin,
10 µM troglitazone, 500 µM 3-isobutyl-1-methylxanthine (IBMX), and 1 µM
dexamethasone). Cells would be maintained under differentiation media for 8-10
days, with media replaced every 48 hours.

Insulin, troglitazone, IBMX and

dexamethasone were all obtained from Sigma Aldrich.
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Differentiation of adipocytes from 3T3-L1 was adapted from a protocol provided
by Beibei Zhu at the University of Kentucky. 3T3-L1 cells would be grown until
48 hours post-confluence in DMEM+10% FBS. At this time, the media would be
replaced with media supplemented with 3% FBS, 10µg/ml bovine insulin, 500µM
IBMX, 10µM troglitazone, 1µM dexemethosone for three days. After these three
days, this media was replaced by media supplemented with 3% FBS, 10µg/ml
bovine insulin and 1µM dexemethosone for six days, with media replaced every
48 hours.
Oil red O staining of cultured cells
At time of Oil Red O (ORO) staining, media would be drawn off from culture
wells, and wells washed with PBS.

Cells were fixed in 10% formalin for 30

minutes, and then washed again with PBS. Oil red O stain (Sigma Aldrich), was
dissolved in isopropanol and water, filtered and applied to cells for 20 minutes.
At the end of the staining period, the wells were washed with 50% isopropanol,
followed with ddH2O. The wells were then be counterstained with Hematoxylin
(Sigma Aldrich) for 1 minute, and then washed with ddH2O.
siRNA knockdown
siRNA transfections were performed in six-well plates according to manufacturer
instructions. Briefly, 3T3-L1 cells were plated 24 hours prior to transfections at a
density of 106 cells/well. At time of transfection for each well, 1 μg siRNA duplex
constructs would be combined with DharmaFECT 1 transfection reagent (GE Life
Sciences) in a volume of 200 µl serum and antibiotic-free DMEM and allowed to
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complex for 25 minutes. siRNA/ DharmaFECT complexes were added to each
well in serum-free DMEM and permitted to transfect for five hours prior to
replacing media with 10% FBS- supplemented DMEM. siRNA constructs for Par4 and PPARγ as well as control constructs siRNA A and siRNA B were obtained
from Santa Cruz Biotechnology; Dallas, TX. Transfected 3T3-L1 cells were used
for experiments 48-72 hours post-transfection.
Real-time qPCR
Total RNA was extracted from MEFs using an RNeasy Plus mini kit (QIAGEN;
Valencia, CA). cDNA synthesis was performed using an iScript DNA synthesis
kit (Bio-Rad; Hercules, CA). Analysis of gene expression was performed in 96
well plates on a Biorad CFX96 touch Real-Time thermocycler and iQ SYBR
green supermix (BioRad). Samples were run in triplicate and normalized to
GAPDH. Total RNA was extracted from adipose tissue using an RNeasy lipid
tissue mini kit (QIAGEN). qPCR of human adipose cDNA was performed using
an ABI 7900HT (Applied biosystems; Foster City, CA). The following primers
(Table 2.1) for mouse PPARγ1, PPARγ2, mouse GAPDH, mouse Par-4 and
human Par-4 were designed using Primer Blast and sourced from Integrated
DNA Technologies (IDT; Coralville, IA).
Data were analyzed using the ΔΔCt method relative to GAPDH or 18s controls.
Next-gen RNA sequencing and data analysis
Analysis of the transcriptome of Par-4+/+ or Par-4-/- mouse livers was performed
as follows: Total RNA was extracted from liver tissues from three Par-4+/+ or Par46

4-/- mice using RNeasy mini kit (Qiagen) according to manufacturer’s instructions.
The RNA-Seq libraries were prepared using TruSeq Stranded Total RNA Sample
Prep Kit with Ribo-Zero ribosomal RNA depletion (Illumina). The manufacturer’s
protocols were used to sequence ribosomal RNA-depleted libraries at 2×50-bp
paired-end reads on an Illumina HiSEq. 2500 in high-output mode, to an average
depth of 40×106 paired-end reads per sample at the Memorial Sloan Kettering
Cancer Center.
For mapping, following data quality assessments, reads derived from residual
rRNA were removed by aligning (Bowtie2 v2.1.0) against ribosomal RNA
references derived from Ensembl v74 annotations. The RNA-seq datasets were
mapped to the target genome using STAR aligner that maps reads genomically
and resolves reads across splice junctions. We used the two- pass mapping
method in which the reads are mapped twice. The first mapping pass uses a list
of known annotated junctions from Ensembl. Novel junctions found in the first
pass are then added to the known junctions and a second mapping pass is done.
After mapping we computed the expression count matrix from the mapped reads
using HTSeq. The raw count matrix generated by HTSeq was then be processed
by normalizing the raw gene count based on the total reads for each sample, and
average gene count for each group was calculated for identifying upregulated/down-regulated genes. Differentially expressed genes were identified
at a threshold of log2 fold change greater than 0.5. The KEGG Pathway analysis
and translator tools were also used to place genes in specific pathways.
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Cloning
PPARγ2 upstream promoter fragment sequences were amplified from C57/BL6
mouse genomic DNA , utilizing primers shown in Table 2.2. Amplifed fragments
were ligated into the MCS region of a pGL4.14 luciferase reporter vector
(Promega; Madison, WI), and transformed via heat-shock method into DH5α
chemically-competent

E.

manufacturers protocol.

coli

cells

(Invitrogen;

Carlsbad,

CA)

using

Transformed colonies were selected on ampicillin

selection plates, expanded as a liquid culture in liquid LBamp media and plasmids
recovered using a maxiprep kit, following manufacturer’s instructions (Origene;
Rockville, MD).
Luciferase expression assay
Luciferase (luc) reporter assays were performed using a Steady Lite Plus
reporter gene assay kit (Perkin Elmer, Waltham, MA). Briefly: MEFs or NIH 3T3
cells were co-transfected with Luc reporter constructs and β-Gal expression
constructs (in pGL3 vector) in a 96 well plate using Lipofectamine and Plus
reagent (Invitrogen) according to the manufacturers protocol. Cell lysates were
collected 24-48 hours post-transfection in RIPA buffer with appropriate protease
inhibitors (Roche) for each experimental group, combined with Steady Lite
reagent and analyzed using a Perkin Elmer TopCount plate reader, with the
signal normalized to β-Gal expression.
Immunoblotting
Protein extracts from cultured cell lysates were prepared by washing cell culture
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plates in PBS, adding Laemmli buffer and scraping cells into 1.5ml tubes.
Proteins were denatured by boiling in Laemmli buffer for five minutes.
Liver tissue lysates were prepared by grinding liver tissue under liquid nitrogen.
Cell lysis was finalized through addition of RIPA buffer and appropriate protease
inhibitors (Roche).

Total protein levels were normalized using a Bradford

colorimetric assay (Biorad), and proteins denatured by boiling for five minutes in
added Laemmeli buffer.
immunoblotting.

All lysates were subjected to SDS-PAGE and

Antibodies utilized were Par-4 (R-334), leptin (A-20),

adiponectin (N-20), GAPDH (Santa Cruz Biotechnology), PPARγ (Cell Signaling
Technology), and β-actin (Sigma Aldrich). Band density as measured by pixel
counts was obtained using Vision WorksLS software by UVP.
Histology
White adipose tissue samples were harvested from mice, fixed in formalin for 48
hours and washed in PBS. Fixed adipose tissues were embedded in paraffin,
and sliced into 4um sections.

Hematoxylin / eosin stained adipocyte cross-

sectional area was obtained and determined by area analysis of randomly
selected adipocytes using ImageJ (NIH). The average cross-sectional area for
each tissue group is given in results.
Freshly harvested liver tissue requiring Oil-red-O staining was embedded in OCT
embedding compound (Tissue-Tek) and frozen on dry ice. These cryopreserved
livers were sectioned, mounted on slides, stained with oil-red-O and
counterstained with hematoxylin. Sectioning and staining were carried out by the
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Markey Cancer Center Biospecimen ond Translational Pathology Shared
Resource Facility at the University of Kentucky.
Human adipose and plasma samples from lean and obese adults were provided
by the Biospecimen and Translational Pathology Shared Resource Facility at the
University of Kentucky Markey Cancer Center (Grant# P30CA177558).

All

patient information was anonymized, and all work approved by the University of
Kentucky institutional review board.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed utilizing a ChIP-IT High Sensitivity kit (Active Motif;
Carlsbad, CA) according to the manufacturer’s instructions. Briefly: cultured NIH
3T3 cells (~80% confluency), were fixed in a formaldehyde-containing buffer,
which would also fix any DNA-binding protein complexes to the chromatin.
These fixed cells were then lysed by repeated snap-freezing cycles and the
chromatin sheared via sonication using a Bioruptor Pico device (Diagenode),
until the resulting chromatin fragment size was approximately 400-500BP.
Aliquots of recovered sonicated chromatin (15-30μg) was incubated with 4μg of
relevant antibodies overnight at 4˚C. The antibody-bound chromatin was pulleddown using kit-supplied G-protein agarose beads, whereupon the crosslinking
was reversed, the DNA eluted and subjected to qPCR. The antibodies used
were Par-4 (R334) (Santa Cruz), IgG (Santa Cruz)-serving as negative control,
and C/EBPα (14AA) (Santa Cruz) as positive control. See Table 2.3 for primer
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sequences.

ChIP-verified negative and positive control primer sets were

obtained from Active Motif.
Statistical analysis
Results for blood glucose and plasma insulin are expressed as the mean±SEM.
Results for human adipose tissue Par-4 expression are expressed as mean±SD.
All other figures are expressed as mean+SEM. Quantitative data were obtained
through f-test for variance followed by Student's t test in Microsoft Excel.
Significance was assumed for P-values <0.05.
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RESULTS
Chow-fed Par-4 knockout mice are overweight with increased fat mass
Although Par-4 has been previously well established as a tumor-suppressor, our
research group was interested in potential physiologic functions of Par-4. To that
end, we had generated constitutive whole-body Par-4 knockout mice (Par-4-/-),
for which we had maintained observation for 300 days. Our initial cohort used for
determining the growth rates were comprised of two groups of males (Par-4+/+
and Par-4-/-; n=8 mice per group). Final weights were compiled from a total of 30
age-matched mice per group.
An observation which readily became apparent during regular weigh-ins, is that
the chow-diet-fed Par-4-/- mouse population began to gain weight at a
significantly greater rate than that of the wild-type controls (Par-4+/+), as shown
by the divergent weight gain curves (Figure 2.3 A,B).

By the end of the

observation period (300 days), the mean weight of the Par-4-/- mice was 54g as
opposed to 32g for the Par-4+/+ animals. Upon sacrifice and dissection, gross
anatomic observations yielded that the Par-4 knockout animals displayed greatly
enlarged gonadal (epidydimal) and subcutaneous fat pads. EchoMRI analysis
indicated that fat was responsible for a significantly greater percent of body mass
in knockout mice. (Figure 2.3C). A comparison of organ weights between the
two populations indicated no significant differences between the mass of the
heart, spleen or kidneys (kidneys weighed as a pair), (Figure 2.3D). However,
the knockout livers were much larger (Figures 2.3 D, 2.4 A), and displayed signs
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of significant lipid accumulation, as shown by oil red O staining of neutral lipids
(Figure 2.4 B).

Furthermore, as lipids are synthesized, repackaged and

processed in the liver, we sought to determine whether plasma lipid levels were
altered in the Par-4-/- mice. Results indicate that both plasma triglyceride and
cholesterol levels were significantly elevated at about 12 months in the Par-4
knockout mice, compared to age-matched Par-4+/+ controls (Figure 2.4 C).
As our data indicated increased adipose tissue accumulation between the Par4+/+ and Par-4-/- mouse populations, we investigated whether this could be
attributed primarily to enlargement of the individual adipocytes (hypertrophy) or to
expansion of the adipocyte population (hyperplasia).

Gonadal fat pads from

multiple timepoints were fixed in formalin, paraffin embedded, sectioned and H+E
stained. Microscopy revealed hypertrophy in the adipocytes of knockout mice as
young as three months of age. This observation was recapitulated at 18 months
of age (Figure 2.5 A,B).
Continuing our characterization of the obese mice, we characterized the relative
production of the adipose-specific hormones leptin and adiponectin. Gonadal
adipose tissue lysates from the 12 month-old Par-4-/- mice indicated significantly
elevated leptin (Figure 2.6 A) and reduced adiponectin (Figure 2.6 B)
expression, compared to Par-4+/+ controls.
Chow-fed Par-4 knockout mice are hyperinsulinemic
In order to determine whether glucose homeostasis might be dysregulated, we
performed OGTT to obtain whole-blood glucose and plasma insulin curves which
53

would show fasting (time=0 on graphs) and post-glucose administration levels. It
was found that Par-4-/- mice had blood glucose response curves which were
comparable to controls, although the fasting glucose was elevated in the Par-4-/animals (Figure 2.7 A). However, the insulin curves indicate the glucose levels
were kept in check only though significantly enhanced insulin secretion from the
pancreas. This is evidenced by the significantly elevated insulin levels in the
Par-4-/- mice at all timepoints in the experiment (Figure 2.7 B).
Par-4 / SAC overexpressing mice weigh less than controls
Given our observations that Par-4 loss leads to enhanced weight gain, we
wanted to determine whether overexpression of Par-4 would reduce weight gain.
For this, we reexamined prior weight data from age-matched mice from an
earlier, unrelated study. The animals utilized in this study stably overexpressed
Par-4, the SAC domain or a GFP control gene in all tissues (see: Introduction,
pg.6).

We found that the mass of the Par-4 and SAC-overexpressing mice

weighed significantly less than the GFP control mice (Figure 2.8). Unfortunately,
as retrospective data, we could not determine whether this was due to
differences in the fat content of the animals.
Par-4-/- mice have an altered metabolic profile
Use of metabolic cages can generate much useful information regarding the
mouse metabolic phenotype. Physical activity levels are measured by mounting
the cage in an array of infrared (IR) emitters and detectors, which would detect
movement as the IR beam path is obstructed by the mouse between the emitter
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and detector. Food and water uptake is monitored by hanging the food/water
sources on individual load sensors which report removal of the food or water.
Oxygen consumption (VO2) and CO2 production (VCO2) are determined by
drawing air samples from the cage at 30 minute intervals, measuring the O2 and
CO2 levels and comparing those values with those of an unoccupied reference
cage. This gas data can be used to determine the respiratory exchange ratio
(RER)- the ratio of VCO2/VO2. These gas measurements are also utilized to
calculate the resting and total energy expenditure (REE / TEE). The REE refers
to the number of calories required by the body during an inactive 24hour period.
The TEE refers to the number of calories required by the body during a full 24
hour period- including active states. Housing chow-fed Par-4+/+ and Par-4-/- mice
in metabolic cages revealed several features of the two mouse lines as shown in
(Figure 2.9). Firstly, relative to lean mass, there was no observed difference in
caloric intake between the Par-4+/+ and Par-4-/- mice (Figure 2.9 A), although It
was observed that the Par-4-/- mice displayed reduced activity during the
recording phase (Figure 2.9 A). Paradoxically, however, the Par-4-/- mice also
recorded elevated total energy expenditure and resting energy expenditure
(Figure 2.9 B). We also observed an elevated 24 hour RER in the Par-4-/animals (Figure 2.9 B). An RER value of 1.0 or more indicates energy source of
pure carbohydrate, a value of 0.70 indicates one of pure fat, and 0.85 indicates a
combination of the two. This is because more oxygen is required to oxidize fatty
acids than glucose (Shmidt-Neilson, 1997). All values obtained for RER are
between 0.75 and 0.90, thereby the animals are using a mix of the two energy
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substrates.

However the elevated VCO2/VO2 ratio in the Par-4+/+ mice is

indicative of a more carbohydrate based energy substrate as opposed to fatty
acid oxidation based metabolism.
Par-4 Inhibits adipogenesis in vitro
In light of the excess adipose tissue development observed in the Par-4 knockout
mice, we hypothesized that Par-4-depleted fibroblasts may be more likely to
differentiate into adipocytes. For our first experiments, we treated post-confluent,
early-passage (Passage <10) primary MEFs with adipocyte differentiation media
as described under Materials and Methods. The plates were fixed, stained with
oil red O, and scored by manually counting oil red O positive or negative cells in
five randomly selected fields. Under these conditions, the Par-4 knockout MEFs
were far more readily differentiated than wild-type MEFs, as demonstrated
visually (Figure 2.10 A), and analytically (Figure 2.10 B).

To follow up the

above results, we examined the adipogenesis trends in a 3T3-L1 pre-adipocyte
model. This was done as 3T3-L1 cells represent a standard model for in vitro
adipogenesis. To this end, prior to differentiation, we knocked down (KD) Par-4
and/or PPARγ by transfecting the L1 cells with scrambled control siRNA, Par-4
siRNA (mouse), PPARγ siRNA (mouse) and lastly: co-transfected Par-4 and
PPARγ siRNA. As expected: after differentiation and ORO staining, the Par-4
KD cells (50% reduction in Par-4 expression) showed significant increases in the
number of ORO positive cells compared to controls. By contrast: the PPARγ KD
cells (75% reduction in PPARγ expression) displayed a reduction in the number
of ORO positive cells compared to controls, whereas the combined PPARγ/Par-4
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KD line was not significantly different from controls. Western blots for Par-4,
PPARγ and GAPDH are provided to demonstrate successful knockdown (Figure
2.11 A).
Par-4 overexpression inhibits adipogenesis
As

our

previous

results

established

that

Par-4

knockdown

enhances

adipogenesis in vitro, we decided to investigate whether this effect could be
neutralized through adenovirus-mediated overexpression of Par-4. Similar to the
previous experiment, transfection of 3T3-L1 cells with Par-4 siRNA (generating
an approximately 30% reduction in Par-4 expression) significantly enhanced
adipogenesis over cells transfected with control siRNA. Identical results were
obtained through transduction of a GFP-control adenovirus to both siRNA
groups. However, transduction of a Par-4- containing adenovirus to both siRNA
groups (control and siPar-4) resulted in significant abrogation of adipogenesis in
the siPar-4 group and a minor reduction of adipogenesis in the si-control group
(Figure 2.11 B).

Western blots for Par-4 and GAPDH are provided to

demonstrate successful knockdown or overexpression. Note that: adenoviruses
were administered 24-48 hours after siRNA transfection, and approximately 24
hours prior to addition of differentiation media to the cells.
Adipocyte-specific Par-4 knockout generates an obese phenotype
We have observed that Par-4 loss enhances adipogenesis in vitro and the Par-4
knockout mice are obese. We then hypothesized that adipocyte-specific ablation
of Par-4 would likewise lead to weight gain in vivo, which promped us to examine
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the same parameters in adipocyte-specific Par-4 knockout mice (Par-4/AKO) as
we had our Par-4-/- mice.

we have found the Par-4/AKO mice experienced

significantly greater weight gain by 3-4 months of age compared to the floxed
control mice (Par-4Fl/Fl). This trend continued to be observed by 5-6 months of
age (Figure 2.12 A). EchoMRI analysis of the six-month mice demonstrated that
the Par-4/AKO mice had a much-higher percent body fat. Likewise, dissection of
the six-month old mice revealed greatly enlarged gonadal and subcutaneous fat
pads in the Par-4/AKO animals compared to Par-4Fl/Fl controls (Figure 2.12 B).
Weighing the liver, heart, spleen and kidneys (kidneys weighed as a pair),
indicated the only significant difference between these organ sets was in liver
weight (Figure 2.12 C). Furthermore: reminiscent of the Par-4-/- mice, histology
indicated that the adipocytes of the gonadal fat pads display hypertrophy in the
adipose Par-4/AKO mice (Figure 2.13). As an interesting observation, the livers
in the Par-4/AKO mice were found to be significantly enlarged and oil red O
stained liver sections displayed signs of fat accumulation. (Figure 2.14 A).
However, despite the enhanced adipodosity and fatty livers observed in the
adipocyte-specific Par-4 knockout mice(Figure 2.14 B), there was no significant
difference recorded in the plasma triglyceride and cholesterol levels between the
experimental and control groups (Figure 2.14 C).
Furthermore, while OGTT indicates Par-4/AKO and control mice have similar
fasting blood glucose levels (Time=0 on graph), we observe that administration of
the glucose bolus caused the glucose response curve of Par-4/AKO mice to
diverge greatly from controls, with mean blood glucose spiking at 400 mg/dl
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compared to approximately 200mg/dl for the controls.

Ultimately the blood

glucose levels for both groups return to baseline levels by the 120 minute mark
(Figure 2.15 A). Following up with insulin ELISA utilizing the plasma samples
collected at the OGTT timepoints indicates that like the Par-4-/- mice, Par-4/AKO
mice are hyperinsulinemic at all timepoints that were tested (Figure 2.15 B).
Par-4/AKO mice have an altered metabolic profile
Housing chow-fed control and Par-4/AKO mice in metabolic cages revealed the
following features of the two mouse lines (Figure 2.16). Relative to lean mass,
there was an evident difference in caloric intake between the two lines per 24
hour period (Figure 2.16 A), seemingly showing increased feeding in the Par4/AKO mice. Further, there was no observed difference in activity during the
recording phase (Figure 2.16 A). However, the Par-4/AKO mice were recorded
displaying elevated resting energy expenditure (EE) (Figure 2.16 B). There was
also observed an elevated Par-4/AKO 24 hour and resting respiratory exchange
ratio (RER) (Figure 2.16 B). The elevated VCO2/VO2 ratio in the Par-4/AKO
mice is again indicative of a more carbohydrate- based energy substrate as
opposed to fatty acid oxidation based metabolism.
Adipogenesis downregulates Par-4
In the course of the in vitro adipogenesis experiments, I compared Par-4 protein
expression between simultaneously plated groups of Par-4+/+ MEFs which had or
had not received the adipocyte differentiation media.

We found that the

differentiated cells consistently exhibited sharply downregulated Par-4 (Figure
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2.17). Thereby, the adipogeneic pathway is capable of rapidly downregulating a
known tumor suppressor.
Par-4 is downregulated in obese human subjects
Given that obesity is linked to tumorigenesis, and Par-4 loss is also linked to
spontaneous tumorigenesis, coupled with our finding that adipogenesis
downregulates Par-4, we were intrigued by the possibility that obesity might
downregulate Par-4 expression.
downregulation

as

a

If verified, this effect would implicate Par-4

contributory

mechanism

for

obesity-associated

tumorigenesis. Taking this further, we could hypothesize that downregulation of
Par-4 is a prerequisite for adipogenesis and obesity.
qPCR using primers for human Par-4 and normalizing to amplification of 18S
revealed significant reduction of Par-4 in the abdominal white adipose tissue
obtained from 10 obese (BMI≥30) human subjects compared to 10 lean (BMI≤25)
subjects (Figure 2.18 A). This result was reinforced by a follow-up experiment
involving an independent cohort of obese and lean human subjects (n=10 in each
group). In this experiment, protein lysates (from abdominal white adipose tissue)
and plasma were obtained from the subjects and subjected to Western blotting,
probing for Par-4, or GAPDH as a control. Plasma lysates utilized coomassiestained albumin as a loading control. This indicated that not only was Par-4
protein expression reduced in obese adipose tissue, but circulating Par-4 levels
were likewise reduced in 80% of individuals examined (Figure 2.18 B,C).

60

Par-4 is downregulated in dietary-obese mice
After the observed Par-4 downregulation in obese human subjects, we attempted
to replicate these findings experimentally. Specifically, we wanted to determine
whether obese wild-type mice would exhibit reduced Par-4 levels in body tissues
and plasma. the mouse model would also allow us to determine Par-4 levels in
non-adipose tissues, such as the lung and liver. We elected to use a dietary
obesity model, feeding randomly assigned C57/BL/6 wild-type mice either
exclusively a high-fat diet (HFD) (60%Kcal from fat), or a control diet (10% Kcal
from fat). Mice from both groups were sacrificed after 16 weeks, with tissues and
plasma harvested.

Adipose, liver and lung tissue was subjected to Western

blotting for Par4 and GAPDH. Plasma was probed for Par-4 and albumin used
as a loading control.
Weight and body fat content as measured by EchoMRI was significantly elevated
in the HFD mice from 5 weeks onwards compared to time-matched control-diet
mice (Figure 2.19 A).

By 16 weeks, Par-4 was found to be markedly

downregulated in the adipose, liver and lung tissue (Figure 2.19B), as well as
the plasma of the HFD mice (Figure 2.19C).
Par-4 regulates genes which promote obesity
RNAseq was performed on liver RNA due to the liver's heavy role in lipogenesis,
which would provide the greatest likelihood of finding Par-4 target factors in the
lipogenic pathway. RNAseq data is summarized in Table 3.1. A number of
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genes were found to be upregulated in the Par-4-/- mice which are associated
with regulation of adipogenesis, lipogenesis, lipid transport and lipolysis.
PPARγ1 expression is inversely associated with Par-4 status
Given the established role of PPARγ in adipogenesis and the fact that an obese
phenotype with significant lipid accumulation are observed in the adipose and
liver tissues, I decided to investigate whether PPARγ expression could be
regulated by Par-4. My initial investigations involved Western blotting of lysates
for Par-4+/+ and Par-4-/- MEFs, as well as adult mouse (Par-4+/+ and Par-4-/-) lung
primary fibroblasts and liver lysates, probing for PPARγ and actin.

PPARγ was

found to be upregulated in all examples of the Par-4-/- samples- at least PPARγ1
isoform (Figure 2.20 A,B). To verify this finding wasn’t solely applicable to mice,
this experiment was repeated using lysates from human lung tumor cell lines
A549 and HOP92.

These two cell lines had been modified with either a

scrambled control shRNA construct or a Par-4 shRNA construct, thus generating
Par-4 knockdown cell lines and selected with puromycin. Western blotting again
demonstrated PPARγ upregulation in both A549 Par-4 knockdown (A549 Sh-P4)
and HOP92 Par-4 Knockdown

(HOP92

Sh-P4) lines (Figure

2.20C).

Collectively, these experiments demonstrate that loss of Par-4 consistently leads
to the upregulated expression of PPARγ (at least PPARγ1) in mouse and human
models.
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Par-4 transcriptionally inhibits PPARγ1
As we have to this point observed upregulated expression of PPARγ under
conditions of Par-4 loss or downregulation, we hypothesized that this may be due
to

a

transcriptional

mechanism

as

opposed

to

(for

example)

ubiquitination/proteosomal activity affecting PPARγ at the level of the protein.
We tested this via real-time qPCR, of cDNA synthesized from the RNA of Par-4+/+
and Par-4-/- MEFs, utilizing primers for Par-4, PPARγ1 and GAPDH.

After

normalizing for GAPDH, we observed significant transcriptional upregulation of
PPARγ1 in the Par-4 knockout MEFs (Figure 2.21).
Par-4 overexpression inhibits PPARγ
Having observed the upregulation of PPARγ under conditions of Par-4 ablation,
we decided to test whether the opposite may be true, that Par-4 overexpression
would suppress PPARγ. Par-4 was overexpressed in 3T3-L1 cells (which were
found to best tolerate the procedure compared to MEFs) through use of a Par-4
containing adenovirus. A GFP construct-containing adenovirus was selected as
the control. Lysates were obtained from both groups of transduced cells 48
hours after infection, and subjected to Western blotting- probing for PPARγ, Par4 and GAPDH. The Par-4-infected fibroblasts were found to express significantly
less PPARγ1 and PPARγ2 than the GFP-containing cells (Figure 2.22).
Par-4 inhibits transcriptional activity of the PPARγ2 promoter
As we’ve demonstrated PPARγ to be transcriptionally repressed by Par-4, it
would seem that Par-4 is acting as a transcriptional repressor. Since there is no
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current evidence that Par-4 is capable of direct DNA binding (there are no basic
amino acid regions flanking the LZ domain of Par-4), it would appear that Par-4
may bind another DNA-binding protein and is thereby acting as a transcriptional
co-repressor. Our first step towards investigating this is to determine whether
Par-4 is capable of affecting the activity of the PPARγ promoter.

Given the

previously observed effects upon adipogenesis, we decided to focus our efforts
upon the promoter for mouse PPARγ2. We first generated a series of luciferase
(luc) constructs (inserted into a pGL4.14 luc reporter vector), using sequences
from the 3KB region upstream of the start codon (ATG site).

Our initial luc

constructs included, respectively, the entire 3KB upstream region (Fragment 1/
Frag 1), the distal 1.6KB region (Frag 2) and the 1.6KB region proximal to the
ATG site (Frag 3) (Figure 2.23A). The sequences for Frag. 2 and Frag. 3 were
designed to overlap by approximately 260BP to include any sites on the margins
between the two.

These constructs (as well as an empty pGL4 luc vector

control) were co-transfected along with a β-Gal expression construct into Par-4+/+
and Par-4-/- MEF’s, incubated for 48 hours and subjected to a luciferase
expression assay and normalized to βGal activity. Initial results showed that
luciferase expression and thereby transcriptional activity was enhanced in Par-4-/MEFs transfected with Frag. 1 and Frag. 3. By contrast, the luciferase activity of
Frag. 2 is comparable to that of the empty vector control, regardless of Par-4
status (Figure 2.23B). This indicates that not only does Par-4 status affect
PPARγ2 promoter activity, but Par-4 mediates this activity within 1.6 kb of the
start codon.
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To further narrow down the promoter region at which Par-4 will affect PPARγ2
promoter activity, we generated additional luc constructs by designing and
inserting subfragments of Frag.3’s sequence into the same luc reporter vector as
before. These subdivisions were approximately 450BP in length, and overlapped
the adjacent fragment sequences by approximately 100BP (Figure 2.24 A).
Utilizing the same luc reporter assay as before in Par-4+/+ and Par-4-/- MEFs, we
found that Par-4-/- MEFs generated greatly enhanced luc activity (compared to
Par-4+/+ MEFs) when transfected with a construct containing Frag. 6.

No

significant difference in activity was observed from the other fragments tested.
These results indicate that Par-4 acts (directly or indirectly) upon a sequence
between 580 and 996 bp upstream of the transcription initiation site of the
PPARγ2 promoter (Figure 2.24 B).

Additional trials (data not shown)

demonstrated frag 6 would generate luc activity comparable to frag 1 and frag 3.
Nuclear localization of Par-4 is required for regulation of PPARγ2 promoter
Given that Par-4 can be found in multiple cellular compartments, we wanted to
determine whether nuclear localization of Par-4 is required for the previously
observed effects upon the PPARγ2 promoter.

If true, this would lend credence

to the hypothesis that Par-4 is acting upon the chromatin. To accomplish this, I
made use of

pGL3-based constructs which would contain either a complete

cDNA clone of rat Par-4 or deletion mutants of rat Par-4 for which either nuclear
localization sequence had been deleted (designated ΔNLS1 or ΔNLS2). We
then then co-transfected each of these constructs (or an empty pGL3 control
vector) with either Frag.6 or an empty luc vector.
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All groups would also be

transfected with a β-Gal construct for normalization. Our intent was to compare
the effects of transfecting complete Par-4 to ΔNLS1 or ΔNLS2 with regards to
Frag. 6 luc activity. Proceeding with the luc reporter assay revealed that cotransfection with the complete Par-4 construct significantly inhibited the luc
activity from Frag. 6.

This result was replicated by co-transfection with the

ΔNLS1 mutant, however, co-transfection with the ΔNLS2 mutant completely
abrogated the effects of Par-4 (Figure 2.25). Based upon these results, we
conclude that NLS2 and therefore nuclear localization of Par-4 is required for
Par-4-mediated regulation of PPARγ2.
Chromatin Immunoprecipitation indicates Par-4 binds PPARγ2 promoter
By this point we have established that nuclear entry of Par-4 is a requisite for
transcriptional repression of the PPARγ2 promoter.

As such, to determine

whether Par-4 actually binds (directly or indirectly) to the chromatin and thereby
act as a component of a corepressor complex in this region, we utilized
chromatin immunoprecipitation (ChIP) analysis.

This would allow us to

determine whether an anti-Par-4 antibody would pull down the genomic
sequence region corresponding to Frag. 6.
For our first trial, we transfected NIH 3T3 cells with either a pGL4.14 control
vector, a Frag. 6- containing construct or a Frag. 7- containing construct. As
previous luc experiments indicated that Frag. 7 does not respond to the presence
of Par-4 (Figure 2.24 B), we chose to use it as an additional negative control.
The fixed and fragmented chromatin from all transfection groups was subjected
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to pull-down with either a Par-4 antibody or IgG control antibody. The resulting
ChIP DNA for all groups was subjected to qPCR, utilizing primers specific to
Frag. 6, Frag. 7 or a negative control primer (designated P6, P7 and NP,
respectively). After the qPCR data was normalized to GAPDH in the input DNA
for all groups, we were able to conclude that the Par-4 antibody but not the IgG
antibody was able to pull down the sequence corresponding to Frag. 6. Further,
the Par-4 antibody did not pull down Frag. 7 (Figure 2.26 A).
While the previous ChIP experiment demonstrated Par-4 binding to a transfected
Frag. 6- containing construct, we wanted to conclusively demonstrate that Par-4
could pull-down the endogenous promoter sequence of interest. To this end, we
fixed, recovered and fragmented a larger quantity of native chromatin from NIH
3T3 cells and performed pull-down with antibodies for Par-4, IgG and C/EBPα.
The C/EBPα is intended as a positive control as Frag. 6 is predicted to contain a
putative C/EBPα binding site (“JASPAR 2018,” n.d.). For the purposes of this
experiment, qPCR was performed utilizing primers P6 and NP and GAPDH
positive input control primer pair. The results again show significant amplification
of the Frag. 6 sequence in the Par-4 and C/EBPα antibody pull-down groups
compared to the IgG antibody pull-down group (Figure 2.26 B). From this we
can conclude that Par-4 is capable of binding to a chromatin element within a
specific region of the PPARγ2 promoter sequence under native conditions.
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Table 2.1: qPCR primers utilized.
Target

Fw Primer (5’-3’)

Rv Primer (5’-3’)

Mouse Par-4

AGAATGAAGCTGCGACCCTC

ATCTTCTGGGGCACTGGTTG

Human Par-4

CTGCCGCAGAGTGCTTAGAT

TGCATCTTCTGCTTTCCGCT

GTCTCGGTTGAGGGGAC

TGTCAACCATGGTAATTTCAGT

CACTGCCTATGAGCACTTCA

ACAAATGGTGATTTGTCCGT

AAATGGTGAAGGTCGGTGTG

TGAATTTGCCGTGAGTGGAG

GTAACCCGTTGAACCCCATT

CCATCCAATCGGTAGTAGCG

Mouse
PPARγ1
Mouse
PPARγ2
Mouse
GAPDH
Human 18s
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Table 2.2: PPARγ2 upstream promoter sequence primers. All Fw primers were
designed to include a Kpn1 restriction site, and all Rv primers include a
Xho1restriction site. Primers for fragments 6 and 7 were also utilized for the
ChIP assays (Figure 2.26).

Fragment

Fw Primer (5’-3’)

Rv Primer (5’-3’)

1

GAGTGGTACCGTAAGCAACATTTATTG

GAGCCTCGAGAACAGCATAAAACAGAG

2

GAGTGGTACCGTAAGCAACATTTATTG

GCCCCTCGAGTTTAACTTGAATTCTTA

3

GCCGGGTACCTTTTACATTCTAGACAC

GAGCCTCGAGAACAGCATAAAACAGAG

4

GAGTGGTACCTTTTACATTCTAGACAC

GAGCCTCGAGGGTCTAAATATCAGTCA

5

GAGTGGTACCCATCATTTGGACTACTG

GAGCCTCGAGGCCTTTGCCCTTTTTGG

6

GAGTGGTACCGCTCTTTTAAAGTCCAC

GAGCCTCGAGAGGTCCAAAATGTTACT

7

GAGTGGTACCGATAGATAAACAAATTT

GAGCCTCGAGGTACAGTAGTTGGAATT

7+8

GAGTGGTACCGATAGATAAACAAATTT

GAGCCTCGAGAACAGCATAAAACAGAG
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Table 2.3: ChIP primers

Primer Pair

Fw Primer (5’-3’)

Rv Primer (5’-3’)

6

GCTCTTTTAAAGTCCACAAGTCACTG

GGAAAACTCTGGCTTCTTGCTTAA

7

ATGTGTGATTAGGAGTTTCAACCAAA

GAATTACCAGAGCAGAGATTGTTCA

Proprietary sequence

Proprietary sequence

Proprietary sequence

Proprietary sequence

Designation

Mouse
Negative
Control
Primer Set 2
Mouse
Positive
Control
Primer Set
(GAPDH)
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Table 2.4: Obesity-associated genes upregulated in Par-4-/- mouse liver relative
to Par-4+/+ mouse liver, as determined by RNA-Seq.

Genes

Log(2)

Adipogenesis

(KO/WT)*
RGS16

3.823

CD36

2.236

ELOVL6

2.181

SCD1

2.058

FASN

1.653

ACC1

1.247

LipoFatty
Lipogenesis acid
lysis
uptake
X

X

X

Function

Inhibition of β-oxidation
Fatty acid uptake; regulation of
lipogenesis and adipogenesis

X

X

Elongation of long-chain fatty acids

X

Synthesis of monosaturated fatty
acids

X

Synthesis of long-chain saturated
fatty acids

ACC2

1.498

Synthesis of fatty acid; Inhibition of
fatty acid and glucose oxidation;
enhances fat storage

Lpin1

1.179

Synthesis of triglycerides;

X

X

SREBP1

1.011

X

Required for
transcription

X

Regulation of lipogenesis

SLC27A1 0.689
PPARγ

X

X

0.654

adipogenic

Fatty acid uptake
Regulation of lipogenesis

X

X
and adipogenesis
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gene

Fig 2.1: Strategy for constitutive whole-body knockout of Par-4 in mice
LoxP sites targeting the second exon and locations of genotyping primers '27, 28
and 30' (A).

Par-4+/+, Par-4+/- and Par-4-/- mice are genotyped by PCR (B).

Western blotting of various tissues in the Par-4+/+ and Par-4-/- mice, showing the
reduced Par-4 protein levels (C).
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Figure 2.2: Adipocyte-specific Par-4 KO (Par-4/AKO) genotyping and
protein expression
Genotyping results from fl/fl controls and Par-4/AKO (adipocyte-specific Par-4
KO) mice (A). Tissue protein expression of Par-4, demonstrating knockdown
specificity to adipocytes, as opposed to the stromal-vascular fraction (SVF) or
liver tissue (B).
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Figure 2.3: Chow-fed Par-4 knockout mice are overweight with increased
fat mass
Chow-fed whole-body male knockout mice (Par-4-/-) are significantly heavier than
wild-type control animals (Par-4+/+) by 300 days of age (n=30 per group) (A).
Growth curves composed from weigh-ins from male mice (n=8 per group)
demonstrate divergence between 50 and 300 days of age (B). Also, the Par-4-/mice were found to carry significantly larger gonadal and subcutaneous fat pads
compared to Par-4+/+ (n=30 mice per group).

EchoMRI readings likewise

confirmed that the Par-4-/- mice contained a far greater percentage of their mass
as fat (C).

Comparing weights of major organs (male mice, n=6 per group)

revealed that the Par-4-/- livers were significantly heavier at 300 days age (D).
(A,B,C,D) (*) indicates statistical significance (P<0.001) by Student’s t test.
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Figure 2.4: Par-4-/- mice have enlarged, fatty livers and elevated plasma
lipids
The livers of Par-4-/- mice are significantly larger than Par-4+/+ mice by weight
(n=6 male mice per group) (A).

Oil-red-O staining of livers also showed

significantly more staining of the Par-4-/- livers, and thereby more neutral lipid
accumulation (Scale bars 50μm) (B).

Measuring plasma triglyceride and

cholesterol levels from male Par-4+/+ mice (n=10) and Par-4-/- mice (n=9) indicate
the Par-4-/- mice have significantly greater levels of both (C). Mean+SEM are
shown for all graphs.
(A) (**) indicates statistical significance (P<0.001) by Student’s t test. (C) (*)
indicates statistical significance (P<0.05) by Student’s t test.
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Figure 2.5: Par-4-/- mice have enlarged adipocytes compared to Par4+/+ mice
Gonadal white adipose tissue collected from 3 and 18 month pairs of male
Par-4+/+ and Par-4-/- mice show that the Par-4-/- animals possess visibly
larger adipocytes at both age groups (scale bars 200μm) (A). This is
verified by quantification of the cross-sectional area.

Mean+SEM are

shown. (B). Mean+SD are shown for all graphs (n=8).
(B) (*) indicates statistical significance (P<0.005) by Student’s t test.
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Figure 2.6: Par-4-/- mice have altered adipose hormone levels.
Obese 12 month old male Par-4-/- mice express

increased leptin (A) and

reduced Adiponectin (B) in their adipose tissues. Mean+SEM are shown for all
graphs (n=3 mice per group).
(A,B) (*) indicates statistical significance (P<0.01) by Student’s t test.
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Figure 2.7: Par-4-/- mice are hyperinsulinemic compared to Par-4+/+ mice.
OGTT showed only mild elevation of fasting plasma glucose (*) and glucose
response in male Par-4-/- mice (n=7) compared to male Par-4+/+ mice (n=6) and
similar responses to glucose administration (A).

However, the Par-4-/- mice

displayed steeply elevated insulin at all timepoints (B). Mean±SEM are shown for
all graphs.
(A,B) (*) indicates statistical significance (P<0.05) by Student’s t test.
(B) (**) indicates statistical significance (P<0.01) by Student’s t test.
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Figure 2.8: Par-4 and SAC overexpression limit weight gain.
At one year of age, Par-4-overexpressing and SAC-overexpressing mice
weighed significantly less than GFP-transgenic control mice. Mean+SEM are
shown for all graphs (n=6 mice per group).
(*) indicates statistical significance (P<0.01) by Student’s t test.
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Figure 2.9: Behavioral and metabolic profiles of Par-4+/+ and Par-4-/- mice
Metabolic cage recordings of Par-4+/+ and Par-4-/- while fed standard chow
revealed no difference in caloric intake between the two groups. However, the
Par-4+/+ mice proved to be rather more active during the recording period (A).
Furthermore, Par-4-/- mice displayed elevated resting and total energy
expenditure and lower 24 hour RER compared to Par-4+/+ (B). All data was
plotted relative to lean mass (n=8 mice per group).
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Figure 2.10: Par-4 Inhibits adipogenesis in MEFs.
Par-4-/- MEFs more readily differentiate to adipocytes than Par-4+/+ control cells
as shown visibly by Oil-Red-O staining (scale bars 200μm) (A) and after
quantification (B). Data is shown from 5 randomly- selected regions per group.
Three independent experiments were conducted. Mean+SEM are shown for the
graph.
(B) (*) indicates statistical significance (P<0.01) by Student’s t test.
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Figure 2.11: Par-4 inhibits adipogenesis in vitro.
siRNA knockdown of Par-4 (mouse Par-4 siRNA) in 3T3-L1 cells accelerated
differentiation to adipocytes compared to control siRNA.

This effect was

abrogated by co-transfection with mouse PPARγ siRNA (A).

Furthermore,

combining Par-4 KD with Par-4 overexpression via rat Par-4-containing
adenovirus (P) counters the effect of Par-4 loss on adipogenesis (B). Infection
with a control GFP adenovirus (G) had no effect. (Scale Bars 200µm). Three
independent experiments were conducted. Mean+SEM are shown for all graphs
from cell counts of five randomly selected visual fields.
NTC= Non-Transfected/ Transduced Control
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Figure 2.11: Continued:
(A,B) (*) indicates statistical significance (P<0.005) by Student’s t test.
(A,B) (**) indicates statistical significance (P<0.0005) by Student’s t test.
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Figure 2.12: Adipocyte - specific Par-4 knockout (Par-4/AKO) mice exhibit
an obese phenotype.
Adipocyte-specific Par-4 knockout mice (Par-4/AKO) experience significant
weight gain starting around 3-4 months- with a 6-month old male pair shown for
comparison (A). the 6-month male mice have visibly more adipose tissue, as
quantified by echo-MRI (n=6 mice per group) (B).

The organ weights were

similar except for the greatly enlarged livers in the Par-4/AKO mice (C).
Mean+SEM are shown for all graphs (n=6 mice per group).
(A,B) (*) indicates statistical significance (P<0.05) by Student’s t test.
(C) (**) indicates statistical significance (P<0.005) by Student’s t test.
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Figure 2.13: Par-4/AKO mice have enlarged adipocytes
Gonadal WAT from 6 month old male mice was subjected to H&E staining (A)
and cell size quantified (B) (Scale Bar:200µm) Mean+SEM shown for graph.
(B) (*) indicates statistical significance (P<0.005) by Student’s t test.
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Figure 2.14: Par-4/AKO mice have enlarged livers.
Livers were significantly enlarged in the adipocyte-specific Par-4 knockout mice
(Par-4/AKO). Demonstrable increases in size and mass were observed in male,
6 month old Par-4/AKO mice (n=6 mice per group) (A). Oil red O staining of livers
also showed significantly more staining of the Par-4/AKO livers, and thereby
more neutral lipid accumulation (Scale bars 50μm) (B). However, plasma
triglyceride and cholesterol levels were not significantly different (C). Mean+SEM
are shown for all graphs.
(A) (*) indicates statistical significance (P<0.005) by Student’s t test.
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Figure 2.15: Par-4/AKO mice display hyperglycemia and hyperinsulinemia

OGTT of plasma collected from control and Par-4/AKO mice (male, n=6 mice per
group) at six months of age revealed hyperglycemia after glucose administration
(A) and hyperinsulemia (B) in the Par-4/AKO animals. Mean±SEM are shown for
all graphs.
(*) indicates statistical significance (P<0.05) by Student’s t test.
(**) indicates statistical significance (P<0.01) by Student’s t test.
(***) indicates statistical significance (P<0.0001) by Student’s t test.
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Figure 2.16: Behavioral and metabolic profiles of control and Par-4/AKO
mice
Par-4/AKO mice (n=5) are recorded as having increased caloric intake but similar
activity levels compared to controls (n=6) (A).

Further, while there is no

significant difference in the total energy expenditure between the two groups,
Par-4/AKO mice were recorded as exhibiting increased resting energy
expenditure, and increased VCO2/VO2 ratios (B). All data was plotted according
to lean mass.
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Figure 2.17: Adipogenesis downregulates Par-4
Par-4+/+ MEFs differentiated to adipocytes (Adipo) over an 8-10 day period show
significant downregulation of Par-4 as shown by Western blotting. Mean+SEM of
the relative band density of Par-4 relative to GAPDH for three independent
experiments is shown for graph.
(*) indicates statistical significance (P<0.05) by Student’s t test.
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Figure 2.18: Par-4 is downregulated in obese human subjects.
Adipose tissue collected from obese (O) and lean human subjects (L) without
known morbidities show reduced Par-4 RNA levels as demonstrated via qPCR,
compared to lean human subjects (A). A similar effect was observed in adipose
protein expression, as well as plasma Par-4 (B). Analysis showed that 80% of
the obese subjects had reduced adipose and plasma levels of Par-4 (C).
Mean+SEM are shown for all graphs (n=10 adipose and 10 plasma samples per
group).
(*) indicates statistical significance (P=0.0278) by Student’s t test.
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Figure 2.19: Par-4 is downregulated in dietary obese mice.
Body fat composition data for wild-type C57BL/6 mice given control or HFD for
16 weeks (n=3 per group) (A). Mice fed a high-fat diet for 16 weeks showed
reduced Par-4 expression in the adipose tissue, lung and liver, compared to
control diet (B). Furthermore, plasma from the animals showed reduced Par-4
levels in the HFD group (C).
(*) indicates statistical significance (P=0.001) by Student’s t test.
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Figure 2.20: PPARγ1 expression is inversely associated with Par-4 Status
Western blotting of lysates harvested from Par-4+/+ and Par-4-/- mouse embryonic
fibroblasts (MEFs) and adult lung primary fibroblasts (Adult FB) showed
increased expression of PPARγ in the Par-4-/- groups (A). This increase in
PPARγ is also observed in the livers of Par-4-/- mice (B). This was also observed
after stable knockdown of Par-4 (Sh-P4) in A549 and HOP92 cell lines compared
to control (Sh-c) (C).
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Figure 2.21: Par-4-/- MEFs show higher levels of PPARγ1 RNA
qPCR of Par-4+/+ and Par-4-/- MEFs show increased PPARγ1 mRNA levels in the
Par-4-/- cells.

Mean+SEM are shown for all graphs.

Three independent

experiments were perfomed.
(*) indicates statistical significance (P<0.001) by Student’s t test.
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Figure 2.22: Par-4 overexpression inhibits PPARγ expression
3T3-L1 cells were infected with either GFP or GFP-Par-4 adenovirus. Lysates
were harvested and subjected to Western blotting (A). Relative band densitynormalized to GAPDH show reduction of PPARγ1 and γ2 in the Par-4overexpressed group (B). Mean+SEM for three separate experiments are shown
for graph.
(*) indicates statistical significance (P<0.05) by Student’s t test.
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Figure 2.23: Par-4 inhibits transcription of the PPARγ2 Promoter
Overlapping Luciferase constructs were generated from the first 3kb of the
PPARγ2 promoter (A). These constructs, when transfected into Par-4+/+ and
Par-4-/- MEFs indicated that Par-4 suppressed activity of the full-length fragment
(Frag. 1) and the 1.6kb fragment proximal to the ATG site (Frag. 3) (B).
Mean+SEM for three separate experiments are shown for all graphs.
(*) indicates statistical significance (P<0.005) by Student’s t test.
(**) indicates statistical significance (P<0.001) by Student’s t test.
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Figure 2.24: PPARγ2 Promoter fragments utilized for luciferase assays
The 3 KB region upstream of the mouse PPARγ2 ATG site (Frag1) was first
divided into the partially overlapping 1.6 KB fragments (Frag 2 and Frag 3).
Based on luciferase data generated by these fragments, Frag 3 was further
subdivided into fragments 4-8 (A). Luciferase data from these fragments indicate
activity of the construct containing Frag. 6 is inhibited by Par-4 (B). Mean+SEM
for three separate experiments are shown for graph.
(*) indicates statistical significance (P<0.001) by Student’s t test.
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Figure 2.25: Par-4’s effect upon frag.6 is dependent upon nuclear
localization. Co-transfection of Frag. 6 with empty pCB6 vector, intact Par-4 or
Par-4 lacking either of the two nuclear localization sequences (ΔNLS1 or
ΔNLS2), show that not only does overexpression of Par-4 attenuate the luc
activity of the Frag.6-containing construct (ᵻ), however, ΔNLS2 co-transfection
completely abrogates the effect (ᵻᵻ). Mean+SEM for three separate experiments
are shown for graph.
(*) indicates statistical significance (P<0.001) by Student’s t test.
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Figure 2.26: Chromatin Immunoprecipitation (ChIP) indicates that Par-4
binds PPARγ2 promoter
Transfecting NIH 3T3 cells with empty vector, Frag.6 or Frag.7, then pulling down
with either an anti-Par-4 antibody or anti-IgG antibody show that Par-4 is bound
to Frag.6-compared to Frag. 7 (A). Performing the same procedure against the
endogenous NIH 3T3 chromatin (B), verifies Par-4 binding to the PPARγ2
promoter (†). Means of three separate experiments shown.
(*) indicates statistical significance (P<0.05) by Student’s t test.
(**) indicates statistical significance (P<0.001) by Student’s t test.
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CHAPTER THREE: DISCUSSION AND FUTURE DIRECTIONS
DISCUSSION
Par-4 loss promotes obesity and adipogenesis
Due to the ubiquitous nature of Par-4, we sought to determine whether a
physiologic role for Par-4 exists outside of tumor-suppressor activity. Overall,
this study has revealed a significant physiologic function for Par-4, which is
independent of its known tumor-suppressor function.

From this series of

experiments, we have determined that Par-4 inhibits adipogenesis and adipose
lipid storage.

This overall finding has been replicated utilizing cell culture

models, and long-duration in vivo studies.

These in vivo models included

comparisons of constitutive whole-body Par-4 knockout mice against controls
and comparing adipocyte-specific Par-4 knockout mice against controls.

We

have found evidence that Par-4 loss promotes adipogenesis and hypertrophy of
existing adipocytes, resulting in marked fat accumulation and subsequent obesity
of the animals.
In whole-body Par-4 knockout animals, expression of the adipose hormones
leptin and adiponectin are affected (i.e.: adiponectin decreased and leptin
increased in the knockout animals). These observations are typical in obese
subjects (Arita et al., 1999) as paradoxically, adiponectin is downregulated in
obese subjects through hypermethylation of the adiponectin promoter (A. Y. Kim
et al., 2015). Furthermore, while leptin is usually proportional to adipodosity as a
compensatory mechanism by increasing feelings of satiety and thereby reducing
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feeding behavior, there is observed a loss of leptin sensitivity at the
hypothalamus in chronic obesity(Levin & Dunn-Meynell, 2002).

So while the

observed trends in leptin and adiponectin expression are consistent with high
adipodosity, they are likely not causative in this context as the weight differential
was already present at the time of sample collection. Also, prior to the observed
weight gain, metabolic cage data indicated no difference in food intake.
Metabolic cage data on the whole-body Par-4-/- mice indicated that, although
there was increased activity recorded in the Par-4+/+ animals, the effect
disappears in the Par-4/AKO animals compared to controls.

While feeding

behavior is evidently not a factor in the Par-4-/- animals, the Par-4/AKO mice
showed increased caloric intake, although the trendlines have rather different
trajectories.

It would be useful to examine leptin expression in these two

populations to observe whether any difference exists for this marker prior to
weight gain. Furthermore, energy expenditure would not appear to account for
the obese phenotype as the Par-4-/- mice showed increased total energy
expenditure and the Par-4/AKO mice showed no difference compared to
respective control animals. The 24hr RER for both Par-4-/- and Par-4/AKO mice
is however elevated compared to controls.

This indicates that although all

populations are using a mix of carbohydrate and fat for energy (RER between
0.85-0.95)(Shmidt-Neilson, 1997), the Par-4-/- and Par-4/AKO mice are biased
towards carbohydrate rather than fat utilization. This could be accounted for by
the increased expression of genes capable of inhibiting β-oxidation, as shown
below.
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RNA seq data showed that Acetyl-CoA Carboxylase 1 and 2 (ACC1 and ACC2)
levels are both found to be upregulated in Par-4-/- livers. ACC1 increases fatty
acid synthesis, whereas ACC2 inhibits β-oxidation; both enzymes are also found
in adipocytes as well as the liver and other peripheral tissues (Wakil & AbuElheiga, 2009). Upregulation of both would appear to bias the system towards
accumulation of fatty acids. Another possibility is that the elevated levels of Gprotein signaling regulator RGS-16 found in the Par-4-/- mouse livers might be
inhibiting fatty acid oxidation (Pashkov et al., 2011). However, given the current
lack of data regarding the function of RGS-16 in adipose tissue, this would not
explain the obesity and metabolic phenotype observed in the Par-4/AKO mice.
Further investigation might be necessary, perhaps looking at differential
expression of CPT-1 or other mitochondrial enzymes required for β-oxidation.
Increased expression of the fatty acid transporters CD36 and SLC27A1 in the
Par-4-/- mice might also indicate a phenotype biased towards lipid accumulation
in the adipocytes. Knockout of CD36 in mice prevents HFD- induced obesity and
also attenuates inflammatory activity (Cai, Wang, Ji, Meyer, & van der
Westhuyzen, 2012).
We have also found that the livers are enlarged and accumulate fat in both
whole-body knockout and adipocyte-specific Par-4 knockout mice. However, we
note this has been in association with hyperinsulinemia, which was observed in
the whole body and adipocyte-specific knockouts. While the literature is not
always in agreement as to the sequence of events, the literature notes that the
liver can uptake the increased FFAs released from adipose tissue in response to
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insulin.

As was mentioned in the Introduction chapter, hyperinsulinemia is

known to stimulate de novo lipogenesis (DNL). The evidence shows that if Par-4
is directly enhancing DNL, this behavior might be limited to the adipose tissue.
However, further investigation might be warranted- utilizing a liver-specific Par-4
KO mouse (generated by crossing Par-4fl/fl mice with albumin-Cre mice).
Both the Par-4-/- and Par-4/AKO mice displayed acute hyperinsulinemia after
fasting and at all timepoints in the oral glucose tolerance test compared to
controls.

It has been demonstrated that increasing PPARγ activity in the

pancreas promotes insulin secretion (H.-S. Kim et al., 2013). However, as this
occurred in the adipose specific knockout mice as well, we consider this to be a
secondary effect of the adipodosity. We are currently investigating whether the
experimental

mice

demonstrate

adipose

macrophage

infiltration

and

inflammatory markers which would promote this phenomenon.
A potential contradiction of PPARγ’s role in the Par-4 loss situation is that PPARγ
ordinarily improves glucose homeostasis by stimulating glucose uptake. It may
be noted that the plasma glucose levels in the Par4-/- mice are barely higher than
Par-4+/+ mice. However, the plasma glucose after glucose administration is very
much higher in the Par-4/AKO mice. Perhaps elevated PPARγ in the peripheral
tissues in the Par-4-/- mice is able to compensate somewhat for the
hyperinsulinemia, whereas this is less likely in the Par-4/AKO model (less lean
tissue). Performing OGTT/ insulin tests at earlier timepoints might shed light on
this model.
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Mechanistically, we have identified a number of obesity-associated genes which
are regulated by Par-4 status. These include factors which are responsible for
the synthesis and elongation of fatty acids (ACC1, SCD1, ELOVL6, FASN and
Lipin1).

These factors are also expressed in adipose tissue and adipocytes

(Berndt et al., 2007; Matsuzaka & Shimano, 2009; Wakil & Abu-Elheiga, 2009;
Yew Tan et al., 2016; P. Zhang, O’Loughlin, Brindley, & Reue, 2008). Additional
upregulated factors which have been found in adipose tissue are involved in
fatty-acid uptake (CD36, SLC27A1) and transport (FABP) (Bonen, Tandon,
Glatz, Luiken, & Heigenhauser, 2006; Furuhashi & Hotamisligil, 2008; Martin et
al., 2000).

Additionally upregulated are factors which inhibit lipid β-oxidation

(ACC-2, RGS16)-also found in adipocytes (Oh et al., 2005; “RGS-16 gene
(Genecards),” n.d.). Since it is possible to demonstrate the obese phenotype
generated by Par-4 loss solely in the adipose tissue, with associated steatosis
and hyperinsulinemia, we believe that the effects on those organ systems
(hepatic and pancreatic) are secondary to the adipose expansion. However, they
could contribute to the phenotype of the Par-4-/- mice due to the livers role in
lipogenesis.

However, as all the factors described above are also found in

adipose tissue, it would appear that enhanced lipogenesis and reduced βoxidation in the adipose tissue have a role in the obese phenotype observed in
the Par-4-/- and Par-4/AKO mice.
Critically, we have identified the transcription factor and adipogenic master
regulator PPARγ as being regulated by Par-4 at the promoter level, and believe it
to be the primary regulatory element through which Par-4 influences
103

adipogenesis. The supporting data has been gathered from Western blotting,
qPCR, luciferase-based reporter assays and ChIP. These demonstrate that Par4 influence the transcription and expression of PPARγ1 and 2, that nuclear entry
of Par-4 is required for its influence upon PPARγ2 promoter activity, and finally
that Par-4 is capable of directly or indirectly binding to the chromatin of the
PPARγ2 promoter. Together, the data indicate that nuclear Par-4 binds to a
corepressor complex at the promoter for PPARγ2, thereby attenuating its
transcription and consequently reducing the expression of downstream genes,
such as those required for adipogenesis. (Figure 3.1).
Par-4 is downregulated by adipogenesis and obesity
Complimentary to our findings that Par-4 can inhibit adipogenesis and obesity,
we have discovered that in vitro adipocyte differentiation results in the
downregulation of Par-4.

Follow-up in vivo studies have demonstrated that

obesity is not only capable of downregulating Par-4 expression in various tissues,
but also reduce levels of circulating Par-4 in mouse and human subjects. These
findings have interesting implications for cancer studies. Obesity has already
been associated with increased incidence and mortality of several types of
cancer (Kelesidis et al., 2006).There are several proposed mechanisms for this
relationship. However because intracellular and extracellular Par-4 has been
previously found to selectively induce apoptosis in tumor cells (Burikhanov et al.,
2009; Nadia El-Guendy et al., 2003), our observed Par-4 downregulation may be
a contributing factor in this milleau.
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FUTURE DIRECTIONS
Obesity and metabolic disease represent complicated phenomena, with multiple
known causes and intermediate factors.

Although our experiments detailed

herein have demonstrated that Par-4 status inhibits adipogenesis and fat
accumulation, our RNAseq data indicates Par-4 loss increases transcription of a
number of genes responsible for controlling lipid metabolism and transport which
are not demonstrated PPARγ transcriptional targets. Examples include Lipin-1,
ELOVL-6 and RGS-16. It would be reasonable to assume that although PPARγ
is the master adipogenic regulator, that it is not the sole relevant transcriptional
target for Par-4. This opens many possible avenues for investigation.
Another significant aspect of our model recommends further investigation. While
we have found direct evidence of Par-4 interacting with the promoter sequence
for PPARγ2, these experiments have not yet been extended to the promoter
sequences for PPARγ1. Western blotting and qPCR experiments have shown
that protein expression and transcription of PPARγ1 are also affected by Par-4
status. Both isoforms have some common transcription factors like CREB, FOXO1 and C/EBPα/β, so it stands to reason that Par-4 could influence both
isoforms. Due to the significance of PPARγ1 in regulating insulin sensitivity and
metabolism in many tissues, pinpointing Par-4’s role would enhance our
understanding of this regulatory pathway.
As has been previously mentioned, although Par-4 possesses a leucine zipper
domain, it lacks flanking basic amino acid residues which would otherwise allow
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direct Par-4-DNA binding. Since we have shown Par-4 binding to the chromatin
of the PPARγ2 promoter, this indicates that Par-4 must have a protein binding
partner within that region. Par-4 has multiple domains capable of protein-protein
interactions: the LZ is already known to bind to WT-1, and PKCζ; further, a VASA
domain sequence within the Par-4 N-terminal region has recently been found to
bind the E3 ubiquitin ligase Fbxo45 (Hebbar et al., 2017) and the SAC domain
can bind GRP78. Essentially, further studies would be required to determine
which domain (or portion thereof) of Par-4 binds to our hypothesized
transcriptional repressor complex. Furthermore, the binding partner(s) of Par-4
are yet to be identified.

The JASPAR database identifies many putative

transcription factor binding sites within the Frag. 6 sequence which would need to
be individually investigated.
Furthermore, Par-4 is clearly downregulated during adipogenesis in vitro and in
obese mouse and human subjects in vivo. The actual underlying mechanism is
however unclear at this juncture.

Preliminary trials (data not shown), to

determine the effects of individual components of the adipogenesis differentiation
media did not show any individual component to be capable of replicating the
Par-4 downregulation seen in the complete differentiation media. We currently
conclude that the effect of the media components must be an additive or
synergistic one and that further investigation is warranted. Likewise: regarding
the reduced in vivo tissue expression and plasma levels of Par-4, there are
insufficient data to demonstrate the time-course comparing weight gain and Par4 downregulation. While human studies would be impractical, continued and
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thorough dietary-obese mouse time-course studies may better illustrate the
relationship between weight gain and Par-4 expression.
Another potential mechanism underlying reduced plasma Par-4 levels in obese
subjects, might be due to altered expression of secretory proteins in the dietary
obese mice. Rab8b is a GTPase found to be requisite for vesicular secretion of
Par-4 into the extracellular environment (Burikhanov et al., 2017).

Ravshan

Burikhanov was able to find that Rab8B is downregulated in the adipose tissue of
our dietary obese mouse subjects, but this was not replicated in liver or lung
lysates (Figure 3.2).
Another experimental direction that we wish to undertake would be the
investigation of Par-4-mediated therapies for the amelioration of obesity or other
metabolic disorders.

Secretagogues for Par-4, such as chloroquine and

Arylquin-1 could be tested for their ability to affect adipogenesis and lipogenesis
and whether this effect is Par-4 dependent, as opposed to autophagy dependent
in the case of chloroquine. Also, given the role of inflammation in obesity, and
upon the liver, we would like to investigate whether Par-4 loss promotes
inflammation or macrophage infiltration into the adipose, liver or pancreatic
tissues.
SUMMARY
I have identified a novel physiologic regulatory role for par-4, namely regulation
of adipogenesis and lipogenesis, which is capable of preventing obesity in chowfed mice. These findings have been replicated in in vitro and in vivo models.
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This action has been attributed to a number of obesity-related genes, particularly
through discovery of a transcriptional repressor function of Par-4 at the promoter
of PPARγ2. It further appears that Par-4 downregulation is a requisite step for
adipogenic activity.

We therefore believe that as Par-4 is downregulated,

PPARγ2 will be upregulated and fibroblasts will become more prone to
differentiation into adipocytes and promoting lipid storage.
In addition, we have found evidence that dietary induced obesity can lead to
downregulation of Par-4 in multiple tissues in mice and humans as well as
reduced circulating levels of Par-4 in both species.

As intracellular and

extracellular Par-4 are both capable of attenuating tumorigenesis and metastasis,
this finding reveals a novel mechanism for obesity-associated tumorigenesis.
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Figure 3.1: Proposed model for Par-4 regulation of PPARγ transcription.
Cytoplasmic Par-4 is translocated to the nucleus, whereupon it associates with a
currently unidentified DNA binding protein or proteins at the PPARγ promoter,
thereby inhibiting transcription of PPARγ.
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Figure 3.2: Adipose RAB8B expression downregulated under HFD
Western blotting indicated that RAB8B is downregulated in the adipose tissue of
dietary obese mice. We wish to investigate whether reduced secretion of Par-4
might account for reduced plasma Par-4 levels observed in dietary obese mice.
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